

AUTHOR INDEX

A

Aalberse RC, 40
 Abe T, 752, 766
 Abernethy DR, 1066
 Abplanalp H, 807
 Abramson SB, 631
 Accardo S, 958
 Acevedo-Vázquez E, 539
 Acton RT, 601
 Adams ME, 388
 Adams WH, 713
 Adamson TC III, 32
 Agudelo CA, 443
 Ahles TA, 1101
 Ainsworth SK, 97
 Aisen P, 631
 Akizuki M, 935
 Alarcón GS, 601, 721, 1071
 Alcover A, 922
 Aldrich J, 277
 Alegre C, 1073
 Alexander EL, 1245
 Al-Hadidi S, 1061
 Allen JB, 939
 Alonso A, 1281
 Alonso-Ruiz A, 1053
 Alper CA, 516
 Alspaugh MA, 157, 1263
 Altman RD, 277, 479
 Altz-Smith M, 1344
 Alvares V, 1317
 Ament HJW, 1362
 Amor B, 117, 959
 Andersen PA, 113
 Anderson JJ, 1344
 Anderson RJ, 481
 Anderson RS, 58, 1023
 Appel AM, 79
 Armstrong RD, 1438
 Arnaiz-Villena A, 1281
 Arnett FC Jr, 1150, 1245
 Arnold PI, 277
 Arvin AM, 582
 Asa SL, 682
 Asherson RA, 1075
 Athreya BH, 929
 Austen KF, 481
 Avelar-Garnica F, 539
 Avila J, 922
 Awad J, 20
 Awai LE, 574
 Awdeh Z, 516

B

Bach JF, 117
 Bacon PA, 495
 Baker DG, 888
 Baker RS, 313
 Bales P, 250

Balestrieri G, 1130
 Ball RD, 433
 Balleari E, 958
 Ballou SP, 295
 Balza E, 913
 Bank I, 816
 Bankhurst AD, 1095, 1387
 Bardin T, 369
 Barger BO, 601
 Baró J, 1073
 Baron M, 1309
 Barron KS, 1272
 Barthelemy C, 468
 Bartholomew JS, 905
 Barton DD, 1071
 Bashey RI, 180, 1040
 Bassett LW, 1300
 Baumgarten DF, 888
 Baydur A, 1218
 Beckett VL, 1137
 Belcon MC, 1227
 Bell MJ, 495
 Belli JA, 481
 Belmont JB, 459
 Beltrán-Gutierrez J, 1053
 Benavides G, 1317
 Bene MC, 718
 Benner JJ IV, 1428
 Benson CH, 600
 Berczi I, 682
 Berkman C, 258
 Bernstein RM, 1075
 Bias WB, 1245
 Biemond P, 760
 Billingham MEJ, 388
 Billings PB, 477, 1423
 Biundo JJ Jr, 1318
 Blake DR, 495
 Bloch KJ, 552
 Block S, 456
 Blocka KL, 1344
 Bluestone R, 873
 Boivin G, 1190
 Bombardieri S, 1130
 Bonner H, 1428
 Borda IA, 1200
 Bordigoni P, 718
 Borecký L, 597
 Borenstein S, 701
 Borth W, 897
 Boyer JT, 557
 Boyle JA, 238
 Bradley JM, 1101
 Brahn E, 481
 Brandt KD, 208, 398, 675
 Braunstein EM, 26, 1440
 Brenner MB, 250
 Bresnihan B, 599
 Brewer EJ Jr, 516, 1272, 1433

Brighton CT, 1290
 Bromley M, 857, 968
 Brooks AL, 864
 Broom ND, 1028
 Brown HE, 277
 Brown KS, 1411
 Bukowski RM, 951
 Bunch TW, 267, 1315
 Buyon JP, 623
 Byring R, 698

C

Calabrese LH, 951
 Caldwell DS, 606
 Calin A, 1438
 Callahan LF, 864
 Camisa C, 353
 Campbell J, 1086
 Carnemolla B, 913
 Caro XJ, 1174
 Carrera G, 468
 Carroll DJ, 789
 Carson DA, 477
 Caruana JA, 422
 Case DB, 579
 Castellani P, 913
 Caster SA, 545
 Castor CW, 663, 780
 Catalano MA, 1070
 Cathcart ES, 376
 Cats A, 241, 361
 Cattaneo R, 1130
 Cawston TE, 285
 Cervantes A, 1317
 Chaianuay P, 239
 Chan R, 459
 Chao EYS, 1137
 Chapman CM, 845
 Charlton JR, 744
 Chesebro JH, 1137
 Cheung HS, 668, 829
 Chhatwal P, 1061
 Choay J, 117
 Chou C-T, 1107
 Christy WC, 341, 1180
 Cimmino MA, 958
 Clague RB, 1370
 Clegg DO, 689
 Cleland LG, 230
 Clements PJ, 376
 Cloutier J-M, 305
 Coblyn JS, 516
 Cobo LM, 606
 Cohen AS, 349
 Coleman ML, 721
 Collier DH, 1201
 Collins RL, 728
 Collins-Yudiskas B, 277
 Conn DL, 1137

Corbett M, 20
 Costello PB, 422
 Cranley R, 1411
 Cremer MA, 943
 Crisp AJ, 845
 Cupples LA, 1018
 Curd JG, 1405
 Currie TE, 951
 Cutolo M, 913, 958

D

da Roza DM, 1157
 Dagnino R, 291
 Daniels TE, 147
 Dardenne M, 117
 David CS, 1010
 Davis P, 239
 de Gery A, 117
 de Jongh BM, 241
 de la Figuera M, 1199
 de Silva M, 285
 den Butter A, 217
 Deng J-S, 166
 Dequeker J, 1196
 Díaz de Rojas F, 1200
 Diaz-Flores L, 478
 Dieppe PA, 344, 1002
 Doherty M, 344, 1002
 Dorovini-Zis K, 433
 Dougados M, 117
 Doughty RA, 929
 Douglass RR, 976
 Downie E, 174
 Drayer DE, 579
 Drenick EJ, 1300
 Drueke T, 369
 Dryll A, 369
 Duggan DB, 1072
 Durham JB, 157
 Dwyer JP, 888
 Dykman TR, 1336

E

Eanes ED, 1411
 Eaton HM, 13, 522
 Ebsworth NM, 654
 Edelson HS, 631
 Edlow DW, 1245
 Eerenberg-Belmer AJM, 40
 Egger MJ, 376, 721, 1344
 Ehrlich GE, 1070
 Elst P, 217
 Emkey RD, 1050
 Engber W, 852
 Epstein WV, 410
 Espinoza LR, 1046
 Evans CH, 200
 Evans RW, 829
 Eversmeyer WH, 1320

F

Fallahi S, 737
 Falus A, 358
 Fam AG, 119, 708, 1086
 Fan PT, 873
 Fassbender HG, 956
 Faure G, 718
 Fearon DT, 1321
 Federici AB, 1046, 1405
 Felson DT, 1018
 Felton M, 258
 Feng PH, 1440
 Fernandez-Dapica MP, 1281
 Ferri C, 1130
 Festenstein H, 20
 Finerman ML, 873
 Fischbach M, 1234
 FitzGerald O, 599
 Fock KM, 1440
 Fombergstein B, 359
 Ford DK, 1157
 Fossaluzza V, 960
 Fouts R, 313, 797
 Fox RI, 32, 459, 1046
 Fredrickson SR, 120
 Fritzler MJ, 92
 Fujita T, 615
 Fuster V, 1137
 Fye KH, 1201

G

Gall EP, 557
 Gall V, 258
 Gallagher PJ, 495
 Gallup KR Jr, 728
 Gambhari P, 1316
 Gamir ML, 1281
 Ganea D, 1122
 Ganguly M, 623
 Gantes M, 478
 Garcia MC, 1200
 Garcia-Vadillo A, 1053
 Garovoy MR, 1201
 Gaspar A, 1122
 Gay RE, 737
 Gelberman RH, 480
 Gergely P, 719
 Gershwin ME, 807
 Gerster JC, 1190
 Gertler PA, 586
 Ghandur-Mnaymneh L, 305
 Gharavi AE, 1071, 1318
 Giannini EH, 1433
 Gil-Aguado A, 922
 Giusti M, 958
 Given WP, 631
 Glass D, 516
 Gluck OS, 1336
 Godfrey HP, 852
 Goldberg JW, 837
 Goldman M, 701

Gómez-Reino FJ, 1281
 Gómez-Reino JJ, 1281
 González T, 478
 Gooden MA, 557
 Gordo JMA, 1200
 Gordon MA, 780
 Gossen G, 1186
 Grant K, 238
 Graziano FM, 852
 Green FA, 422
 Greenblatt DJ, 79, 1066
 Griffiths MM, 689
 Grozdova MD, 1144
 Guggenmoos-Holzmann I, 833
 Guseva NG, 1144
 Gutiérrez G, 291
 Gutiérrez-Espinosa G, 539
 Gutiérrez-Rodríguez O, 1118
 Guttadauria M, 376, 721, 1344

H

Haapasaari J, 698
 Hack CE, 40
 Hahn BH, 1336
 Hahn TJ, 1336
 Hakim FT, 1411
 Halla JT, 376, 737
 Halverson PB, 789
 Hamabuchi M, 947
 Hamory BH, 591
 Hamza M, 717
 Hanafée WN, 873
 Handley CJ, 905
 Hanly J, 599
 Haralson KM, 1336
 Harden EA, 1306
 Harmatz JS, 1066
 Harmon CE, 166
 Harne L, 1411
 Harper FE, 97
 Harper JA, 713
 Harris ED Jr, 1050
 Harris EN, 1071, 1318
 Hartley RM, 744
 Haverman J, 40
 Hay FC, 20
 Hayes SP, 1344
 Haynes BF, 606, 1306
 Haynes RB, 1227
 Hazelton RA, 233
 Hezleman BL, 285
 Healey LA, 120
 Heinrichs M, 711
 Helfgott SM, 481
 Hendrix RW, 472
 Henrichs AMA, 1362
 Heotis PM, 713
 Herman JH, 79
 Herode A, 701
 Hicks JE, 1076

Hill HR, 704
 Hoch SO, 477, 1423
 Hochberg MC, 1245
 Hoekstra AJ, 1074
 Hoffman RW, 157
 Hoffman WL, 976
 Holdsworth D, 516
 Hollenberg MD, 780
 Hollister JR, 113
 Homma M, 752, 766, 935
 Hoofnagle JH, 104
 Hooyman JR, 1353
 Horgan C, 320
 Hosokawa H, 599
 Hosokawa M, 1063
 Hosono O, 752, 766
 Houk RW, 472
 Howell DS, 186, 193, 305
 Huberman AK, 250
 Hughes GRV, 1071, 1075, 1314, 1318
 Hunder GG, 1210
 Hunt RM, 1290

I

Ihrle EJ, 654
 Ilardi C, 852
 Irigoyen MV, 1281
 Isenberg DA, 132
 Ishii M, 1063
 Iwase R, 883
 Izui S, 1165

J

Jacobs JC, 116, 357
 Jacobs RP, 586
 Jaffe I, 840
 Jageneau AHM, 139
 Jahn H, 833
 Jamner AH, 713
 Jaraquemada D, 20
 Jasin HE, 502, 985
 Jimenez SA, 180, 1040
 Jones EA, 104
 Joven J, 1199

K

Kahan A, 959
 Kalden JR, 833
 Kalovidouris AE, 299
 Kammer GM, 489, 516
 Kang AH, 995
 Kaplan HB, 631
 Kaplan SB, 376, 721, 1344
 Karas B, 404
 Katona G, 1317
 Katz AL, 960
 Katz P, 72
 Katz R, 522, 744
 Kazis LE, 1344

Kerwar SS, 1201
 Kester WL, 1428
 Khan MA, 516
 Khatib G, 1061
 Khatib R, 1061
 Khokhlova JV, 1144
 Khosla RC, 79
 Kilpi A, 462
 Kirkham SE, 845
 Kitajima T, 1290
 Klippel JH, 1081, 1344
 Kobayashi S, 250
 Kohler PF, 574
 Koide J, 752, 766
 Kontinen YT, 462
 Koopman WJ, 601, 737
 Kopolovic J, 822
 Korchak HM, 623
 Korn JH, 174, 826
 Kosaka Y, 935
 Koster JF, 760
 Kovacs K, 682
 Kovarsky J, 1315
 Krane SM, 845
 Krco CJ, 1010
 Kredich DW, 1058
 Kruskemper HL, 961
 Kulomaa M, 462
 Kumagai Y, 1
 Kuntz D, 369
 Kushner I, 295

L

Lachman LB, 995
 Lacković V, 597
 Lagier R, 1190
 Laitinen O, 596
 Lakomek H-J, 961
 Lal S, 472
 Lander P, 1309
 Larson MG, 13, 258, 522
 Lawry GV, 873
 Lazzarin P, 1316
 Leary SL, 943
 Leiden I, 1197
 Lee C, 472
 Lee JH Jr, 72
 Lehman TJA, 939
 Leibold W, 833
 Leijala M, 698
 LeRoy EC, 97, 1254
 Levin RE, 530
 Levinson AI, 109
 Lewis DE, 1272
 Liang MH, 13, 258, 522, 744
 Lidsky MD, 837
 Lience E, 1199
 Lightfoot RW Jr, 468
 Lim UG, 40
 Lipstein-Kresch E, 118
 Lockshin MD, 720
 Lomeo A, 958

Lorenzo B, 579
 Lösch G, 833
 Louie JS, 1378, 1397
 Lovell DJ, 1433
 Lowther DA, 905
 Lowthian PJ, 230
 Lukáč J, 597
 Luthra HS, 1010
 Luzar MJ, 353
 Lynn JT, 1186

M

Mackworth-Young CG, 1071
 1314
 MacLaughlin EJ, 721
 Mahowald ML, 943
 Main DM, 109
 Maini RN, 476
 Maize JC, 97
 Malmström M, 462
 Malone DG, 104
 Mancuso AA, 873
 Mandel GS, 789
 Mandel NS, 789
 Mankin HJ, 49
 Mannik M, 704, 1165
 Manning PJ, 943
 Marcus DM, 1272
 Maricq HR, 97
 Marino C, 118, 382
 Martel-Pelletier J, 186, 193,
 305
 Martin MFR, 344
 Maruyama N, 599
 Masdeu S, 1199
 Masem M, 410
 Masi AT, 1101
 Master R, 258
 Mateo I, 1281
 Mathews JL, 689
 Mathews PM, 1095
 Matlis R, 1066
 Matoková M, 597
 Matsushita M, 1063
 Mazzocchi RA, 200
 McAlpine SW, 1218
 McCarty DJ Jr, 404, 427,
 668, 829
 McCarty GA, 92, 774
 McChesney L, 1234
 McDuffie FC, 1210
 McGuire-Goldring MB, 654
 McLaughlin GE, 694, 839
 McMahon JM, 240
 McNamara E, 522
 Meats JE, 654
 Medsger TA Jr, 1, 125, 645
 Meenan RF, 721, 1018, 1078
 1344
 Mekori YA, 574
 Melton LJ III, 1353
 Menkes CJ, 959

Mercer E, 285
 Meredith KE, 557
 Mery C, 117
 Metcalf JF, 1254
 Michaels RM, 1183
 Michels ML, 606
 Michelson JB, 459
 Michelson PE, 459
 Migliorini P, 1130
 Millan A, 180, 1040
 Miller A, 1186
 Miller JJ III, 330
 Mimori T, 935
 Minota S, 1329
 Mintz G, 291, 539
 Mituszova M, 1074
 Miyakawa Y, 1329
 Moidel RA, 694, 839
 Molano J, 922
 Mollenhauer E, 711
 Molnár É, 1074
 Molony J, 599
 Monachesi M, 958
 Mongan ES, 1218
 Monsees B, 449
 Moore JO, 1306
 Moore LJ, 1370
 Moore SB, 1210
 Moore TL, 1286
 Morales S, 186, 193
 Moreno-Caparrós A, 1053
 Morgan SH, 1314
 Morimoto C, 752, 766
 Morley JJ, 295
 Mort JS, 509
 Mount JD, 728
 Muijsers AO, 1362
 Muir H, 388
 Muller WH, 217
 Mundis RJ, 116
 Muniz O, 186, 193
 Murawski BJ, 13
 Murphy WA, 449, 1336
 Murray WR, 410
 Muther RS, 116

N

Nagy E, 682
 Nakayama DA, 468
 Naparstek Y, 822
 Nardella FA, 1165
 Naveau B, 369
 Neff JC, 353
 Nelson AM, 1353
 Nelson DD, 200
 Nevitt MC, 410
 Nicholas JJ, 1076
 Nienhuis RLF, 1074
 Nies KM, 1397
 Nieto A, 922
 Nojima Y, 1329
 Nusinow SR, 1405
 Nüsslein HG, 833

O

Oakley CM, 1075
 Obach J, 1073
 Ochi T, 883
 O'Dell JR, 113
 O'Donoghue DJ, 357
 O'Duffy JD, 267, 1210, 1315
 O'Fallon WM, 267, 1137,
 1210, 1353
 Oh SJ, 737
 O'Hanlon DP, 1314
 Olds LC, 330
 Oliver JMT, 1200
 Olsen NJ, 502, 985
 Ono K, 883
 Oppenheim JJ, 1411
 Orenstein D, 227
 Osborn TG, 1286
 Osmundson PJ, 1137
 Ostuni P, 1316

P

Palmer DW, 427
 Palmoski MJ, 398, 675
 Paltiel H, 1309
 Panasyuk AF, 1144
 Panayi GS, 1438
 Panetti M, 443
 Pappas SC, 104
 Parodi A, 478
 Parrish JE, 313, 797
 Partridge AJ, 258
 Patel NJ, 1286
 Paton TW, 119
 Paulus HE, 721, 1421
 Payne LE, 864
 Peebles CL, 166
 Pelkonen P, 698
 Pelletier J-P, 186, 193, 305
 Pennebaker J, 238
 Persselin JE, 1378
 Pesonen E, 698
 Peterson M, 530
 Pettijohn DE, 774
 Phadke K, 313, 797
 Piirainen H, 596
 Pincus T, 864
 Pirrone S, 960
 Pisetsky DS, 545
 Pisko E, 443
 Plaas A, 388
 Plotz PH, 939
 Poole AR, 509
 Pope RM, 1234
 Posada de la Paz M, 1200
 Postlethwaite AE, 995
 Potter AR, 495
 Powell DL, 341
 Price CM, 774
 Prins APA, 217
 Provost TT, 1245
 Pruzanski W, 638
 Pulliam JP, 116

Q

Quismorio FP, 1218

R

Rabin L, 104
 Raffanti S, 913
 Ragsdale CG, 663
 Rakic M, 360, 1080
 Ramsey PG, 704
 Rantala-Ryhänen S, 1397
 Ras MR, 1199
 Raskin RJ, 1439
 Raum D, 516
 Reading JC, 376, 721
 Rebora A, 478
 Recklies AD, 509
 Reginato AJ, 570
 Regueiro JR, 1281
 Reichlin M, 1150
 Reidenberg MM, 579
 Reinherz EL, 481
 Reis S, 579
 Reitamo S, 462
 Renart J, 922
 Resnick DL, 357, 564, 694
 Reveille J, 1071
 Rice JR, 606
 Riggs BL, 1353
 Riggs GE, 557
 Riley SD, 1101
 Rittner C, 711
 Roberts DJ, 663
 Rochmis PG, 1079
 Rodnan GP, 1, 125, 645, 1180
 Rogers M, 13
 Roitt IM, 20
 Rongioletti F, 478
 Rossen RD, 516
 Rossi P, 960
 Rothfield NF, 121, 382, 530
 Roumm AD, 645
 Rovenský J, 597
 Rubash HE, 200
 Rubenstein J, 1086
 Rubiés-Prat J, 1199
 Rubin LA, 638, 1086
 Rubinger D, 822
 Russell AS, 596, 838
 Russell JJ, 1186
 Russell RGG, 654
 Rutala PJ, 557
 Rutherford LE, 623
 Ryan LM, 404, 597
 Ryhänen L, 1397
 Ryu J, 49

S

Sailstad DM, 545
 Saiphoo C, 1086

Sale WG, 864
 Salick AI, 357
 Samanta E, 958
 Sams WM Jr, 1071
 Samuelson CO Jr, 376, 689, 721, 1344
 Sanada H, 1063
 Sandberg GP, 943
 Sandy JD, 388
 Sarkozi J, 708
 Sasaki T, 883
 Sassoon CSH, 1218
 Savage RA, 951
 Schattner A, 358, 1072
 Schiller AL, 845
 Schlossman SF, 481
 Schlumpf U, 1076
 Schmid FR, 472
 Schmidt R, 711
 Schnitzer TJ, 433
 Schroenloher RE, 737
 Schultz DR, 277
 Schumacher HR Jr, 1107, 1428
 Schur PH, 13
 Schwartz ER, 58, 1023
 Schwartz RS, 132
 Schwarz HP, 838
 Scopelitis E, 1318
 Searles RP, 1387
 Sebek BA, 951
 Seibold JR, 139, 1314
 Selby CL, 337, 839
 Seltzer SE, 26
 Semble EL, 728
 Senecal J-L, 121
 Shabtai R, 227
 Shader RI, 1066
 Shapiro MS, 227
 Sharp GC, 1263
 Shearer WT, 1272
 Shenkman L, 227
 Shimizu K, 1063
 Shimizu S, 615
 Shiokawa Y, 1
 Shiozawa K, 615
 Shiozawa S, 615, 957
 Shirahama T, 349
 Shoenfeld Y, 132
 Shore E, 552
 Sibbitt WL Jr, 1095
 Sienknecht CW, 357
 Silva B, 1317
 Silver RM, 1254
 Silvestris F, 1387
 Sipe JD, 349
 Skinner M, 349
 Skosey JL, 1122
 Small P, 819
 Smiley JD, 976
 Smith CD, 121, 382, 826

Smith PR, 476
 Smith RD, 826
 Solsky MA, 376, 721, 1344
 Sorber JA, 1183
 Sosman JL, 26, 744
 Spear G, 1122
 Stanley JH, 1254
 Stanley TM, 1300
 Steen VD, 125
 Steffen C, 897
 Stevens MB, 1245
 Stevens RH, 1378
 Stillman PL, 557
 Stobo JD, 1201
 Story MT, 668
 Striker L, 704
 Strong CG, 1137
 Strong L, 516
 Strongwater SL, 433
 Stuart JM, 1010
 Sundstrom WR, 1070
 Susani M, 897
 Swaak AJG, 760
 Swafford J, 13
 Swann DA, 552
 Swartz KH, 663
 Swindell D, 552
 Sybesma T, 217
 Szabo RM, 480

T

Taccari E, 221
 Takai E, 1329
 Takaku F, 1329
 Takano K, 1329
 Takeda T, 1063
 Takeuchi T, 752, 766
 Takiuchi Y, 599
 Talal N, 1234
 Talbot SF, 109
 Tan EM, 166
 Tao XL, 502
 Taragan R, 227
 Tashkin DP, 1218
 Tatsuta E, 349
 Taurog JD, 943
 Tavolato B, 1316
 Taylor J, 258
 Taylor JE, 13, 258, 522
 Taylor RP, 320
 Teitelbaum SL, 1336
 Teller DC, 1165
 Teodorescu M, 1122
 Teodori S, 221
 Terai C, 1329
 Testa MA, 530
 Thompson JJ, 1428
 Thompson M, 522
 Thompson RP, 97
 Tiliakos N, 600

Tincani A, 1130
 Todesco S, 1316
 Tompkins RB, 267
 Torres D, 174
 Tosato F, 960
 Trakat WF, 694
 Trampusch HD, 121
 Treadwell BV, 49
 Treadwell EL, 1263
 Trentham DE, 481, 489
 Treves R, 369
 Trofimova TM, 1144
 Tsuyama K, 883
 Tubbs RR, 951
 Tugwell P, 1227
 Tur-Kaspa R, 822
 Turner RA, 443, 728

U

Ueo T, 947
 Uitto J, 1397
 Urowitz MB, 638
 Utsinger PD, 694

V

Valencia DW, 92
 Valkenburg HA, 241, 361
 van de Stadt RJ, 217, 1362
 van de Water J, 807
 van der Korst JK, 1362
 van der Linden SM, 241, 361
 Vaughan JH, 32, 477, 1423
 Vaughn WK, 864
 Venables PJW, 476
 Vernon-Roberts B, 230
 Vicario JL, 1281
 Vinceneux P, 837
 von der Mark K, 807

W

Waggie KS, 157
 Walker SE, 157, 591
 Wang A-M, 26
 Ward JR, 376, 689, 721
 Ward RH, 1157
 Warren RW, 545, 1058
 Wasserman SI, 841
 Watt I, 1002
 Weart C, 816
 Wei N, 116
 Weinblatt M, 516
 Weinstein A, 376, 530, 721, 1344
 Weiss J, 1397
 Weiss RA, 951

Weissman BN, 26, 744
 Weissmann G, 623, 631
 Welsh KI, 1438
 Wener MH, 704
 West SG, 113
 Whiteside TL, 645
 Wick G, 807
 Wiedel JD, 574
 Wiesenhutter CW, 250
 Wilder RL, 721, 939
 Wilke WS, 951
 Will H, 961
 Williams HJ, 376, 721
 Williams JM, 208
 Williams RC Jr, 1387
 Williamson GG, 238
 Williamson PK, 570
 Willkens RF, 376, 721, 1344
 Wilske KR, 120
 Wilson JG, 1321
 Wilson RW, 1245
 Woessner JF Jr, 305
 Wood DD, 654
 Wooley PH, 1010
 Woolley DE, 857, 968
 Wortmann RL, 404, 468

Y

Yamamoto T, 1063
 Yancey CL, 929
 Yeni P, 837
 Yokohari R, 752
 Yonemasu K, 883
 Yoshida S, 935
 Young A, 20
 Young CL, 32
 Yu DTY, 250
 Yunis E, 516
 Yunus MB, 1101

Z

Zamani A, 26
 Zane S, 719
 Zanen A, 701
 Zardi L, 913
 Zaytoun AM, 72
 Zea A, 1281
 Zea-Mendoza AC, 1053
 Zech M, 961
 Zerwekh JE, 1050
 Ziegler GL, 125
 Zielinski CC, 838
 Ziff M, 502
 Zimmerman TS, 1046, 1405
 Zischka-Konorska W, 897
 Zitnan D, 597
 Zmijewski C, 929
 Zuckner J, 1286
 Zwillich SH, 591

SUBJECT INDEX

Arthritis and Rheumatism, Volume 27, Numbers 1 through 12, 1984

A

- Abortion, polymyositis/dermatomyositis and, 291
- Acetylsalicylic acid; *see* Aspirin; Salicylates
- Acid labile α -interferon, in juvenile arthritis, 582
- Acid phosphatase, in avian scleroderma, 807
- Acromegaly, cervical spine in, 568
- Actinomycin, CTAP-III, plasminogen activator and, 663
- Acute phase reactants, serum C1q, and articular erosions in RA, 883
- Adenocarcinoma, pancreatic, reflex sympathetic dystrophy and, 1183
- Adherent cells, IgM and IgM rheumatoid factor in RA and, 988
- Adjuvant arthritis
 - Mycoplasma pulmonis* infection in rats and, 943
 - pituitary hormones and, 682
 - in rats, 797
- Adjuvant disease, human, cosmetic surgery and, 1
- Adrenocorticotrophic hormone, in adjuvant arthritis, 682
- Age, osteoporotic fractures and, 1353
- Age-associated amyloid deposition in herniated intervertebral discs, 1063
- Alkaline phosphatase
 - phosphorylation of proteoglycans from cartilage and, 1023
 - prednisone and in RA, 1050
 - serum, in renal osteodystrophy, 1086
- α_1 -Antitrypsin deficiency, small airways function in RA and, 728
- α -Interferon, acid labile, in juvenile arthritis, 582
- α_1 -Macroglobulin in RA, 1122
 - metalloproteinase and, in synovial fluid, 285
- α_2 -Macroglobulin-proteinase complexes, experimental synovitis and, 897
- Alveolitis in scleroderma, 1254
- American Rheumatism Association
 - committee for drug evaluation guidelines, 1422
 - criteria for classification of SLE, 530
 - membership survey, 1078
 - 1983 slide competition, 456
- American Society for Clinical Pharmacology and Therapeutics (ASCPT) committee for drug evaluation guidelines, 1422
- Amorphous calcium pyrophosphate, gelatin model of, 789
- Amyloid arthropathy, hands in, 457
- Amyloid deposition, age-associated, in herniated intervertebral disc, 1063
- Androgen levels in men with RA, 958
- Anemia
 - hemolytic, phosphofructokinase and, 116
 - synovial membrane lymphocytes in RA and, 32
- Angioedema, hereditary, von Willebrand factor antigen levels in, 1405
- Angiotensin converting enzyme inhibitor MK 421
 - oral, in systemic sclerosis, 826
 - in RA, 840
- Animal studies; *see* Experimental studies; Guinea pig studies; Mouse studies; Rabbit studies
- Ankle
 - in dracunculosis, 695
 - in POEMS syndrome, 1053
- Ankylosing spondylitis
 - apoprotein A-I in, 1199
 - cervical spine in, 564
 - diagnostic criteria for, 361
 - DISH in cervical spine, 570
 - HLA-B27 antigen in, 241, 838, 1438
 - juvenile, aortic incompetence in, 698
 - lipoprotein cholesterol in, 1199
 - serologic markers in, 961
 - sexual problems in, 217
 - transcutaneous electronic nerve stimulation (TENS) in, 1074
- Ankylosis, progressive, in mice, 1411
- Ant venom, in RA, 277
- Anti- α -interferon antibodies, interferon and, 583
- Antibodies
 - in ankylosing spondylitis, 961
 - anti- α -interferon, 582
 - anticardiolipin, 1071, 1318
 - anticentromere, 121, 125
 - anticollagen, 797, 1201
 - type II, 1010
 - anti-DNA, 701, 1387
 - anti-F(ab')₂ in SLE, 1387
 - anti-La (SS-B) and HLA-DR3, 1245
 - antilymphocytotoxic, 752
 - antinuclear, 579, 1153
 - anti-Ro (SS-A) and HLA-DR3, 1245
 - anti-SS-A staining, 1318
 - anti-T cell in juvenile arthritis, 1272
 - collagen, in murine lupus, 313
 - CTAP-U and, 780
 - drugs and, in RA, 985
 - gold salts and, in RA, 985
 - to human C5 in SLE, 631
 - human natural thymocytotoxic, 599
 - IgG, 132
 - to IgG in RA, 1382
 - IgM, 132
 - to intermediate filaments of cytoskeleton in SLE, 922

Antibodies (*cont'd*)

- monoclonal anti-DNA, 545
- monoclonal anti-type II collagen, 1010
- monoclonal, synovial membrane lymphocytes in RA and, 32
- in myositis, 1150
- native type II collagen in RA, 1370
- OKT8 monoclonal, 752
- penicillamine and, in RA, 985
- polyclonal anti-type II collagen, 1010
- to ribonucleoprotein, 238
- SS-B, 478
- synthesis of, B cells and, in RA, 985
- Antibody-dependent cellular cytotoxicity, hydrocortisone sodium succinate and, 72
- Anti-C3 radioimmunoassay and anti-F(ab')₂ antibodies in juvenile arthritis, 330
- Anticardiolipin antibodies in SLE, 1318
- veno-occlusive disease and, 1071
- Anticentromere antibodies, 121
- in progressive systemic sclerosis, 125
- pulmonary hypertension and, 1075
- Anticollagen antibodies
- in Lewis rats, 797
- in RA, 1201
- Anticomplement activity, IgM rheumatoid factor and, 1130
- Anti-DNA antibodies
- monoclonal, in B6-1pr/1pr mice, 545
- in myasthenia gravis, 701
- in SLE, 1387
- synthesis, 766
- Anti-F(ab')₂ antibodies
- in juvenile arthritis, 330
- in SLE, 1387
- Antigens
- after total lymphoid irradiation, 486
- in ankylosing spondylitis, 961
- collagen and adjuvant arthritis in Lewis rats and, 797
- cytoplasmic, 925
- Ia, 606
- intermediate filament antibodies in SLE and, 922
- microbial, in knee joint arthritis, 1157
- in myositis sera, 1150
- nuclear, 1165
- ocular epithelial surface, 606
- Su in SLE, 1263
- Anti-IgG antibodies in RA, 1382
- Anti-interferon in SLE, 598
- Anti-La (SS-B) antibodies and HLA-DR3 in Sjögren's syndrome, 1245
- Antilymphocytotoxic antibodies in RA with vasculitis, 752
- Antinuclear antibodies
- captopril and, 579
- HEP-2 cells for detecting, in JRA, 1286
- in myositis, 1153
- speckled, anticentromere antibodies and, 92

- Anti-Ro (SS-A) antibodies and HLA-DR3 in Sjögren's syndrome, 1245
- Anti-SS-A antibodies, HEP-2 cells staining of, 1318
- Anti-T cell antibodies in JRA, 1272
- Antithyroid arthritis syndrome, 227
- Antithyroid drugs in thyrotoxicosis, 227
- Anti-type II collagen antibodies in mice, 1010
- Aortic incompetence, progressive, in juvenile ankylosing spondylitis, 698
- Apatite crystals
- in carpal tunnel syndrome, 1190
- in discs, hemodialysis and, 369
- Apheresis, biotechnology of, rheumatic diseases and, 1081
- Apoprotein A-I in RA and ankylosing spondylitis, 1199
- Arteritis, giant cell
- in Chinese patient, 120
- presenting as bilateral stroke, 819
- Arthralgia, renal osteodystrophy and, 1086
- Arthritis; *see also* Periarthritis; Polyarthritis
- acute, 240
- adjuvant, 682, 797, 943
- autoimmunity to collagen in MRL/1 mice and, 313
- chronic, 939
- collagen-induced, 797, 943
- type II, 1010
- cost of treatment, 522
- cricoarytenoid, 873
- Down's syndrome and, 929
- enterococcal, 591
- erosive, 1061
- experimental, 200, 905
- granulomatous, 1061
- infectious, 591, 960
- inflammatory, 797
- juvenile chronic, 568
- juvenile rheumatoid; *see* Juvenile rheumatoid arthritis; Still's disease
- in knee, 1157
- Lactobacillus casei* cell wall-induced, 939
- in leukemia, 1306
- in painting of S. Botticelli, 1196
- pauciarticular, 698, 929
- polyarticular, 929
- progressive, 574
- psoriatic, 376, 1073
- reactive, 250
- rheumatoid; *see* Rheumatoid arthritis
- septic, 591
- 6-sulfanilamidoindazole-induced, 689
- in thalassemia minor, 1076
- wear particle-induced, 200
- Arthritis and Rheumatism*, misuse of statistics in, 1018
- Arthritis Impact Measurement Scales (AIMS) in outcome assessment, 1346
- Arthropathy
- of Down's syndrome, 929
- erosive, renal osteodystrophy and, 1086

Arthropathy (cont'd)

- Articular cartilage chondrocytes, zonal analysis of cytoplasmic components in, 1290
- Articular erosions
 - renal osteodystrophy and, 1086
 - serum C1q and, in RA, 883
- Articular index and thalidomide in RA, 1120
- Articular mastocytosis in RA, 845
- Aseptic necrosis in pancreatitis, 1309
- Aspirin; *see also* Salicylates
 - hydrolase and, 422
 - in scleroderma, 1137
 - time course response in juvenile arthritis, 1433
- Assertiveness-Aggressiveness Inventory in primary fibromyalgia syndrome, 1101
- Asthma, von Willebrand factor antigen levels in, 1405
- Atlantoaxial subluxation
 - of cervical spine in RA, 26
 - computed tomography in, 1440
- Augmentation mammoplasty, connective tissue disease after, 1440
- Auranofin
 - neurotoxicity from high dose of, 1316
 - vs gold sodium thiomalate, 1346
- Aurothioglucose, hepatotoxicity and, 230
- Autoantibodies
 - IgG and IgM in SLE, 132
 - to nuclear antigens in MRL/1 mice, 1165
 - NuMA protein and, 774
- Autoantigens, NuMA protein and, 774
- Autoimmune abnormalities in Down's syndrome, 929
- Autoimmune disease
 - beta-2-immunoglobulin, interferon and, 358
 - immune complex clearance in, 320
 - spontaneous, in autoimmune mice, 157
 - in MRL/1 mice, 1165
- Autoimmune hemolytic anemia, low CR1 in, 1323
- Autoimmune thyroid disease in multicentric reticulohistiocytosis, 344
- Autoimmunity
 - anti-DNA antibodies in B6-1pr/1pr mice and, 545
 - collagen, HLA-DR4 and, in RA, 489
 - in MRL/1 mice, 313
 - monoclonal activation of, in SLE, 638
 - in RA, 985
 - of skin in progressive systemic sclerosis, 645
- Autologous mixed lymphocyte response in RA, 1234
- Azathioprine, compliance with, in RA patients, 1229

B

- B cells and autologous mixed lymphocyte response in RA, 1234
- B6-+/+ mice, lipopolysaccharide and anti-DNA antibodies in, 545
- B6-1pr/1pr mice, monoclonal anti-DNA antibodies in, 545
- Bacteria, *Y. enterocolitica* in Reiter's syndrome, 250
- Balb/c mice, collagen reactivity in, 313
- Basilar interstitial fibrosis in RA, 873

Behçet's disease

- dural sinus thrombosis in, 816
- thrombophlebitis in, 717
- Bence Jones proteinuria, SLE and, 638
- Beta-glucuronidase
 - female hormones and, 623
 - wear particle-induced arthritis in rabbits and, 200
- Beta-2-microglobulin, autoimmune diseases, interferon and, 358
- Bf allotypes in juvenile rheumatoid arthritis, 1281
- Biliary cirrhosis, primary
 - CR1 dysfunction in, 1324
 - multicentric reticulohistiocytosis and, 344
- Bilirubin, methotrexate in psoriatic arthritis and, 376
- Biomechanical tests of hand in scleroderma, 1137
- Biomechanics of human femoral head OA articular cartilage, 1028
- Biotechnology, apheresis and, 1081
- Blood pressure in systemic sclerosis, 826
- Bone
 - computed tomography of, in RA, 26
 - density in RA, 1002
 - effect of glucocorticoids on, 1336
 - MT3 erosions and, in RA, 20
 - in POEMS syndrome, 1054
 - remodeling in RA, 845
 - resorption in RA, 969
- Bone marrow in SLE, 638
- Bone-cartilage junction, osteoclasts and chondroclasts in RA, 968
- Book Reviews
 - American Academy of Orthopedic Surgeons: Symposium on Heritable Disorders of Connective Tissue*, 479
 - Care of the Arthritic Hand*, 479
 - The Clinical Management of Systemic Lupus Erythematosus*, 720
 - Infection in Joint Replacement Surgery: Prevention and Management*, 1080
 - Maladies dites Systématiques—Systemic Diseases*, 360
- Bovine articular cartilage
 - phosphorylation of proteoglycans from, 1023
 - proteoglycan biosynthesis following leukocyte elastase transferase of, 905
- Bromocriptine in adjuvant arthritis in Fisher rats, 682
- Bronchoalveolar lavage in scleroderma, 1254
- Bullous lupus erythematosus rash, Dapsone and, 1071
- Bursitis
 - iliopectineal, inguinal swelling and, 239
 - rheumatoid chyliform, rheumatoid nodules and, 221
- Button test, in RA, 864
- Bypass arthritis, features of RA in, 1300

C

- C3 receptor abnormalities in SLE, 1321, 1329
- C3b/C4b receptor; *see* C3 receptor; CR1
- C4 allotypes in juvenile rheumatoid arthritis, 1281

- C4B*3 allele in RA, 516
 C4B*3:HLA-15, DR4, BF*S, C2*C, C4A*3, C4B*3 extended haplotype, chromosome 6 and, in RA, 516
 C57BL/6J mice, Sjögren's syndrome and, 157
¹⁴C-acetylsalicylic acid, GAG synthesis and, in canine knee cartilage, 398
⁴⁵Ca-labeled hydroxyapatite crystals, solubilized by canine synovial cells, 829
 Calcaneal insufficiency fractures in pancreatitis, 1309
 Calcific retropharyngeal tendinitis, acute, neck pain and, 708
 Calcific tendinitis, acute, of hand, confusion with periarthritis, 337
 Calcinosis
 anticentromere antibodies and, 121, 125
 cutaneous, in scleroderma, 457
 mitogenic effects of hydroxyapatite in, 668
 Calcium
 in glucocorticoid-induced osteopenia, 1336
 prednisone and, in RA, 1050
 in sarcoplasmic reticulum in polymyositis, 299
 Calcium hydroxyapatite crystals
 ⁴⁵Ca-labeled, solubilization by synovial cells, 829
 mitogenic effects of, 668
 in progressive ankylosis of mice, 1411
 Calcium oxalate crystals in synovial fluid, 458
 Calcium phosphate clearance from rabbit joints, 427
 Calcium pyrophosphate dihydrate (CPPD) crystals
 calcium phosphate crystal clearance and, 427
 in carpal tunnel syndrome, 1190
 cartilage NTP pyrophosphohydrolase, 404
 gelatin model of, 789
 mitogenic effects of, 668
 in RA, 1002
 soft tissue swelling from, 1428
 Calcium pyrophosphate dihydrate (CPPD) crystal deposition disease; *see* chondrocalcinosis
 Calcium transport in progressive systemic sclerosis and RA, 1144
 Calcium uptake crystals and nuclide uptake, 668
 CALLA; *see* Common acute lymphoblastic antigen
 Canine synovial cells, ⁴⁵Ca-labeled hydroxyapatite crystals and, 829
 Canine synovial fibroblasts, hydroxyapatite stimulated ³H-thymidine uptake in, 668
 Capillary ectasia, nailfold biopsy in connective tissue diseases and, 97
 Capsulitis, shoulder, 719
 Captopril
 antinuclear antibodies and, 579
 intolerance of, in systemic sclerosis, 826
 in RA, 840
 Carcinoma
 metastatic renal cell, polymyalgia rheumatica and, 116
 primary epidermoid, distal phalangeal, 452
 Cardiac involvement
 anticentromere antibodies and, in PSS, 125
 Cardiac involvement (*cont'd*)
 in Down's syndrome, 929
 Cardiolipin in SLE, 132
 Cardiorespiratory arrest after total lymphoid irradiation in RA, 481
 Carpal tunnel syndrome with CPPD and apatite crystals, 1190
 Cartilage
 allogenic, wear particle-induced arthritis in rabbits and, 200
 articular
 collagenous network of, 1028
 CPPD in, 789
 effects of loading on, 675
 femoral head OA, biomechanical state of, 1028
 fibronectin on surface of in RA, 615
 immobilization and damage to, 208
 knee, biosynthesis in, in experimental OA, 388
 neutral proteases and proteoglycans in, 305
 in OA, 46
 phosphorylation of proteoglycans from, 58, 1023
 proteoglycan biosynthesis following leukocyte elastase treatment, 905
 zonal analysis of cytoplasmic components in, 1290
 biochemical composition of, 308
 canine knee, salicylate and indomethacin in GAG and PGE₂ synthesis in, 398
 degradation, leukocyte elastase treatment and, 905
 destruction, pannus and, in RA, 956, 957
 effect of salicylates and indomethacin on GAG synthesis in, 398
 erosion, cell types in, 857
 hyaline, erosions in, in RA, 968
 injury, chemically-induced, 208
 knee, collagenolytic activity in wear particle-induced arthritis, 200
 metabolism, effect of stress on, 675
 osteoclasts and chondroclasts in, in RA, 968
 proteoglycans in OA and, 305
 wear particle-induced arthritis in, in rabbits, 200
 Cartilage nucleoside triphosphate (NTP) pyrophosphohydrolase, identification of as an ectoenzyme, 404
 Cartilage subcellular fractionation, NTP pyrophosphohydrolase and, 193
 Cartilage-pannus junction, histopathology of, 857
 Cartilaginous labrum, deformed, hip pain caused by, 947
 Catalase in RA synovial fluid, 760
 Cathepsin in rheumatoid synovium, 509
 CBA/J mice, colchicine inhibition of SAA and SAP synthesis in, 349
 CD 1 Swiss mice, polymyositis induced by coxsackievirus B1, Tucson strain, 433
 Cell wall of *Lactobacillus casei* in induced arthritis in rats, 939
 Cellular immune response to collagen arthritis in Lewis rats, 797

- Cellular immunity and HLA-DR4 in RA, 489
- Central nervous system involvement, acute, in SLE, 1058
- Cerebrospinal fluid in SLE transverse myelitis, 1059
- Ceruloplasmin in RA synovial fluid, 760
- Cervical spine
- acute calcific retropharyngeal tendinitis and, 708
 - computed tomography and radiography of in RA, 26
 - DISH in, in ankylosing spondylitis, 570
 - fracture in DISH, 472
 - hyperostosis in, 564
 - instability in Down's syndrome, 929
 - lesions of, hemodialysis and, 369
 - ossification in, 557
- Chemotactic peptide-stimulated superoxide anions, female hormones and, 623
- Chest expansion in diagnosis of ankylosing spondylitis, 361
- Children with connective tissue disease, anti-T cell antibodies in, 1272
- Chlamydia/Ureaplasma* antigens in knee joint arthritis, 1157
- Chlorambucil in multicentric reticulohistiocytosis, 344
- Chloroquine, mononuclear cell factor and, 888
- Cholesterol, lipoprotein, in RA and ankylosing spondylitis, 1199
- Chondrocalcinosis, 1003; *see also* Calcium pyrophosphate dihydrate crystals
- CPPD in cartilage in, 789
 - knee in, 458
 - CPPD crystal deposition in, 1002
 - NTP pyrophosphohydrolase in, 186, 193
- Chondroclasts in subchondral erosion sites in rheumatoid joint, 968
- Chondrocytes
- biosynthetic activity of in experimental OA, 388
 - CTAP-U and, 780
 - human interleukin-1-like factor and, 654
 - cytokine modulation of proteinase release by, 79
 - knee immobilization, cartilage damage and, 206
 - zonal analysis of cytoplasmic components of, 1290
- Chondroitinase ABC, phosphorylation of proteoglycans from cartilage and, 1023
- Chondrosarcoma, phosphorylation of proteoglycans from, 1023
- Choroiditis, von Willebrand factor in, 1046
- Chromosomal locus 93D, antibodies in ankylosing spondylitis and, 961
- Chromosome 6, haplotypes of in adult RA, 516
- Chromosomes in diagnosis of ankylosing spondylitis, 961
- Chromozym-Try, α_2 -macroglobulin in RA and, 1122
- Chronic arthritis; *see* Arthritis
- Chronic inflammation; *see* Inflammation
- Chronic pain profile in primary fibromyalgia syndrome, 1101
- Chronic polyarthritis; *see* Polyarthritis
- Chrysotherapy; *see* Aurothioglucose; Gold therapy; Gold sodium aurothiomalate
- ^{14}C -hyaluronic acid, CTAP-U and, 780
- Circulating immune complexes
- C1 and, in RA, 40
 - IgM rheumatoid factor synthesis and, in RA, 502
- Cirrhosis, primary biliary, multicentric reticulohistiocytosis and, cytotoxic agents in, 344
- Clinical rheumatology, 1079
- Clinical trials, outcome assessment of, 1346
- Clonally restricted anti-IgG antibodies in RA, 1382
- Clostridia discitis, gas production and, 960
- Coagulation, platelet-inhibiting drugs in scleroderma and, 1157
- Colchicine
- chloroquine inhibition of mononuclear cell factor and, 888
 - serum amyloid A inhibition by, 349
- Collagen
- autoimmunity and HLA-DR4 in RA, 489
 - autoreactivity of, in murine lupus, 313
 - cAMP and calcium transport in, in PSS and RA, 1144
 - fibrils, on articular cartilage, 615
 - HLA-DR4 and reactivity to, 1201
 - metabolism
 - in avian scleroderma, 807
 - in TSK mouse, 180
 - metalloproteinase and, in rheumatoid synovial fluid, 285
 - network, of articular cartilage, 1037
 - synthesis in PSS, 1148
 - type II
 - arthritis in Lewis rats and, 797
 - free native, 1010
 - native, antibodies to, 1370
- Collagen-anticollagen immune complexes in RA synovial fluid, 1370
- Collagen-induced arthritis
- Mycoplasma pulmonis* infection in Lewis rats and, 943
 - in rats, 797
 - type II, in mice, 1010
- Collagenase
- cytokines, chondrocyte proteinase release and, 85
 - in detecting collagen-anticollagen immune complexes, 1370
 - inhibitors of, in rheumatoid synovial fluid, 285
 - Perls' ferric iron and, 495
 - production of, by mononuclear cells, 1397
 - rheumatoid synovial, α_2 -macroglobulin-proteinase and, 897
 - in wear particle-induced arthritis in rabbits, 200
- Collagenolytic activity in knee cartilage in wear particle-induced arthritis, 200
- Common acute lymphoblastic antigen (CALLA) in leukemia-associated arthritis, 1306
- Complement
- C1 activation, lack of, in RA, 40
 - C1q, circulating immune complexes and, in RA, 40
 - articular erosions and, in RA, 883
 - C3
 - anti-F(ab')₂ antibodies and, in juvenile arthritis, 330

Complement (*cont'd*)

- lupus band test and, in detecting rheumatic diseases, 382
- C3b receptor (CR1), red blood cells, immune complexes and in SLE, 320
- C4, lupus band test and, in detecting rheumatic diseases, 382
- C5-derived peptides, in SLE, 631
- C5a desarg, in SLE, 631
- IgM rheumatoid factor and, 1130
- in RA, 737
- receptor abnormalities in SLE, 1321, 1329
- typing of in juvenile rheumatoid arthritis, 1281
- Complement-fixing dsDNA/anti-dsDNA immune complexes in SLE, 320
- Complement-mediated functions, IgM rheumatoid factor and, 1130
- Compliance with treatment in RA, 1227
- Computed tomography in RA
 - of craniocervical region 26, 1439, 1440
 - laryngoscopy and, 873
- Concanavalin A
 - chloroquine inhibition of mononuclear cell factor and, 888
 - total lymphoid irradiation in RA and, 486
- Concanavalin A-induced suppressor T cells in RA with vasculitis, 752
- Congestive heart failure and pregnancy in systemic sclerosis, 295
- Conjugal progressive systemic sclerosis, 1180
- Conjunctivae, in sterile corneal ulceration in RA, 606
- Conjunctivitis in PN and other autoimmune mice, 157
- Connective tissue
 - activation of, 780
 - cathepsin B and, 509
 - fibroblast heterogeneity and, 174
 - interleukin-1 and, 654
 - TSK mouse model of scleroderma, 180
- Connective tissue activating peptide III, 663
- CTAP-U and, 780
- Connective tissue disease; *see also* Mixed connective tissue disease
 - after cosmetic surgery, 1, 1440
 - anti-T cell antibodies in children with, 1272
 - inherited, avian scleroderma, 807
 - labial salivary gland in Sjögren's syndrome and, 147
 - NuMA protein in, 774
 - undifferentiated, in Sjögren's syndrome, 1247
- Constipation and thalidomide in RA, 1118
- Corneal ulceration, sterile, in RA, 606
- Corticosteroids; *see also* Glucocorticoids
 - in giant cell arteritis presenting as bilateral stroke, 819
 - in granulomatous arthritis in Crohn's disease, 1061
 - osteoporotic fractures and, 1353
 - pulse therapy, effect on T cells in Still's disease, 718

Corticosteroids (*cont'd*)

- thiotepa and in RA, 864
- in transverse myelitis in SLE, 1058
- Cosmetic surgery, connective tissue disease after, 1, 1440
- Coxsackievirus B1 (Tucson strain), polymyositis induced by, 433
- ¹⁴C-proline, in TSK mouse model of scleroderma, 183
- CR1 in SLE, 1321, 1329
- Craniocervical region, computed tomography of, in RA, 1439, 1440
- C-reactive protein, articular erosions, serum C1q and, in RA, 883
- Creatinine phosphokinase in RA, 737
- CREST syndrome
 - anticentromere antibodies and, 121, 125
 - cystic lesions of lung in, 935
 - naifold biopsy in, 97
 - speckled antinuclear antibodies in, 92
- Cricothyroid arthritis, basilar interstitial fibrosis in RA and, 873
- Crohn's disease, granulomatous arthritis in, 1061
- Cryoglobulinemia (type II), pseudoleukocytosis and, 353
- Cutaneous/arthritis syndrome in pancreatitis, 1309
- Cutaneous calcinosis in scleroderma, 457
- Cutaneous lesions, neutrophil aggregating activity in SLE and, 635
- Cutaneous polyarteritis nodosa, progressive arthritis and, 574
- Cutaneous SLE, subacute, pulse methylprednisolone in, 837
- Cutaneous vasculitis, after total lymphoid irradiation in RA, 481
- ¹⁴C-xylose, cartilage load and, 675
- Cyclic nucleotides in progressive systemic sclerosis and RA, 1144
- Cycloheximide, CTAP-III, plasminogen activator and, 663
- Cyclophosphamide in multicentric reticulohistiocytosis, 344
- Cysteine, NTP pyrophosphohydrolase in cartilage and, 186
- Cysteine proteinase, cathepsin B in rheumatoid synovium, 509
- Cystic deformation of labrum acetabulare, hip pain caused by, 947
- Cystic fibrosis, anti-F(ab')₂ antibody in, 330
- Cystic lesions in lung, in CREST syndrome, 935
- Cysts
 - corticated, CPPD in RA and, 1002
 - epidermoid inclusion, of hand, 449
- Cytokine modulation of chondrocyte proteinase release, 79
- Cytoplasmic components of articular cartilage chondrocytes, zonal analysis of, 1290
- Cytoskeleton, intermediate filaments of in SLE, 922
- Cytotoxic factor, natural killer, in SLE, 1095
- Cytotoxicity
 - antibody-dependent cellular, hydrocortisone and, 72
 - lymphocyte-mediated, hydrocortisone sodium succinate and, 72

Cytotoxicity (*cont'd*)
natural killer cell, in SLE, 1095

D

DBA/2 mice, Sjögren's syndrome and, 157
Degenerative joint disease; *see also* Osteoarthritis
lubrication by synovial fluid in, 552
Delayed hypersensitivity in collagen and adjuvant arthritis in
Lewis rats, 803
Denatured DNA (dDNA) in SLE, 132
Dendritic cells in rheumatoid lesions, 857
Deoxynucleic acid; *see* DNA
Depression in SLE and RA, 13
Dermal fibroblasts in progressive systemic sclerosis and RA,
1144
Dermal fibrosis in avian scleroderma, 807
Dermal-epidermal junction
IgG and, in primary fibrositis, 1174
lupus band test and, in detecting rheumatic diseases, 382
Dermatomyositis
antibodies in, 1150
nailfold capillary patterns in, 458
Dermatomyositis/polymyositis, pregnancy and, 291
Dexamethasone
chemotactic peptide-stimulated superoxide anion and, 623
CTAP-III, plasminogen activator and, 663
Diabetes mellitus
insulin-dependent, digital sclerosis and, in children, 478
non-insulin-dependent
digital sclerosis in, 960
flexion contractures in, 960
Dialysis, joint disease and, 1086
Diffuse histiocytic lymphoma, knee pain and spinal cord in,
341
Diffuse idiopathic skeletal hyperostosis (DISH), 1074
cervical fracture and paraplegia complicating, 472
cervical spine in, 565
in ankylosing spondylitis, 570
Diffuse scleroderma, anticentromere antibodies in, 125
Digital sclerosis
juvenile diabetes and, 478
in non-insulin-dependent diabetes, 960
Digital ulcerations in systemic sclerosis
ischemic, ketanserin in, 139
reserpine for, 1314
1,25-Dihydroxyvitamin D in glucocorticoid-induced osteo-
penia, 1336
Dipyridamole in scleroderma, 1137
Disability
osteoporotic fractures and, 1353
total hip arthroplasty and, 410
Disease-modifying antirheumatic drugs (DMARDs), evalua-
tion guidelines for, 1421
Disc, herniated intervertebral, amyloid deposition in, 1063

Disease activity
in ant venom-treated RA, 279
in RA, in sterile corneal ulceration, 606
small airways function and, in RA, 728
Disease status in SLE, 638
DISH; *see* Diffuse idiopathic skeletal hyperostosis
Distal interphalangeal joint, renal osteodystrophy and, 1086
Distal phalangeal erosive lesions, 449
Dithiothreitol, NTP pyrophosphohydrolase in cartilage and,
186
DNA
anti-DNA antibody synthesis in SLE and, 766
cartilage stress and, 675
in skin of TSK mouse model of scleroderma, 180
Dopaminergic agents in adjuvant arthritis in Fisher rats, 682
Dorsolumbar spine in ankylosing spondylitis, 361
Down's syndrome, arthropathy of, 929
Dracunculosis, rheumatic syndromes and, 694
Drowsiness, thalidomide in RA and, 1118
Drugs; *see also* Aspirin; Corticosteroids; Glucocorticoids;
Nonsteroidal antiinflammatory drugs; Salicylates
actinomycin, 663
angiotensin converting enzyme inhibitor MK 421, 826, 840
antithyroid, 227
aspirin, 1137
auranofin, 1316, 1346
aurothioglucose, 230
azathioprine, 721, 1229
captopril, 579, 826, 840
chlorambucil, 344
chloroquine, 888
colchicine, 349, 888
compliance with by RA patients, 1227
corticosteroids, 819, 1058, 1353
cyclohexamide, 663
cyclophosphamide, 344
dexamethasone, 663
dipyridamole, 1137
Enalapril, 826, 840
fenoprofen, 1433
FDA guidelines for evaluation of, 1421
gold sodium thiomalate, 985, 1346
gold therapy, response to, 1210
hydroxychloroquine, 267, 1315
indomethacin, 398
methimazole, 227
methotrexate, 376, 599
methylprednisolone, 837
nifedipine, 959
NSAID, 929, 1199, 1227, 1421, 1433
penicillamine, 267, 721, 985, 1223, 1229, 1315, 1362
platelet-inhibiting, 1137
propylthiouracil, 227
in RA, 869
reserpine, 1314
salicylates, 398

Drugs (cont'd)

- sulfhydryl, 840
- thalidomide, 1118
- thiotepa, 864
- tolmetin, 1433

Dry eyes in NZB/NZW and PN mice, Sjögren's syndrome and, 157

Dural sinus thrombosis, in Behçet's disease, 816

Dysgeusia, penicillamine in RA and, 721

E

Ectoenzymes, cartilage NTP pyrophosphohydrolase, 404

Edema

- ketanserine and, in systemic sclerosis, 139
- thalidomide in RA and, 1118

Effector cells, natural killer activity and, in SLE, 1095

Effusions

- cellular, wear particle-induced arthritis in rabbits and, 200
- synovial, synovial membrane lymphocytes and, in RA, 32

Elderly, ibuprofen absorption and disposition in, 1066

Enalapril

- in RA, 840
- in systemic sclerosis, 826

Enchondroma of hand, 450

End-stage renal disease, joint disease in, 1086

Endocrinopathy in POEMS syndrome, 1053

Endothelial cells in polymyalgia rheumatica, 1114, 1115

Endothelial injuries, intravascular leukoaggregates in SLE and, 631

Enteric antigens in knee joint arthritis, 1157

Enterococcal arthritis, 591

Enterococcus, 591

Enzymes

- α_2 -macroglobulin in RA and, 1122
- aspirin survival in vivo and, 422
- cartilage NTP pyrophosphohydrolase, 404
- metalloproteinases and, 285
- NTP pyrophosphohydrolase in cartilage and, 186, 193
- in wear particle-induced arthritis, 200

Eosinophilic fasciitis, toxic oil syndrome, scleroderma and, 1200

Epidermal growth factor receptors in synovial membrane lymphocytes in RA, 32

Epidermal growth factor—urogastrone, CTAP-U and, 780

Epidermoid carcinoma, primary, distal phalangeal, 452

Epidermoid inclusion cyst of hand, 449

Epinephrine, cAMP and calcium transport in scleroderma and RA, 1144

Epithelial mitotic activity in nailfold biopsy in connective tissue diseases, 97

Epstein-Barr virus, RANA and, 476

Epstein-Barr virus-associated nuclear antigen (EBNA), polymorphism of, 1423

Erosions

- articular, renal osteodystrophy and, 1086

Erosions (cont'd)

- serum C1q and, in RA, 883
- of bone in RA, 965
 - HLA-DR, Dw antigens in, 20
 - MT3 specificities in, 20
- cartilage, hyaline and mineralized, in RA, 965
- of cervical spine in RA, 26
- CPPD in RA and, 1002
- distal phalangeal, 449
- in early RA, 744
- intervertebral disc, hemodialysis and, 369
- protease, proteoglycans and in cartilage, 305
- in RA, 267
- renal osteodystrophy and, 1086
- subchondral, chondroclasts and osteoclasts and, in RA, 968

Erosive arthritis

- in Crohn's disease, 1061
- in early RA, 744

Erosive arthropathy, renal osteodystrophy and, 1086

Erosive azotemic osteoarthropathy, 1086

Erosive rheumatoid arthritis, serum C1q and, 883

Erythema in ant venom-treated RA, 277

Erythrocyte CR1 abnormalities in SLE, 1322, 1329

Erythrocyte esterase, aspirin survival in vivo and, 422

Erythrocyte sedimentation rate

- after glucocorticoids in giant cell arteritis, 1046
- in RA, 267, 737

articular erosions and serum C1q in, 883

azathioprine and, 721

mast cells and, 845

synovial membrane lymphocytes and, 32

thalidomide and, 1118

sexual function and, in RA and ankylosing spondylitis, 217

Erythrocytes, aspirin survival and, 422

Esophagus in avian scleroderma, 807

Esterase

- in avian scleroderma, 807
- erythrocyte, aspirin survival in vivo and, 422

Estradiol, neutrophil responsiveness in vitro and, 623

Estrogens, osteoporotic fractures and, 1353

Experimental studies

arthritis

- chondrocyte biosynthesis in, 388
- proteoglycan biosynthesis after leukocyte elastase, 905
- wear particle-induced in rabbits, 200
- synovitis from α_2 -macroglobulin-proteinase complexes, 897

Eye

- sterile corneal ulceration in RA, 606
- von Willebrand factor and in giant cell arteritis, 1046

F

F344/N rats, *Lactobacillus casei* cell wall-induced arthritis in, 939

Fab fragments, CTAP-U and, 780
 Familial progressive systemic sclerosis, 1181
 Fasciitis, eosinophilic, toxic oil syndrome, scleroderma and, 1200
 Fc fragments
 CTAP-U and, 780
 IgM rheumatoid factor and, 1130
 Female hormones, neutrophil responsiveness in vitro and, 623
 Femoral articular cartilage damage, immobilization and, 208
 Femoral condyle
 cartilage, effect of stress on, 675
 immobilization, cartilage damage and, 208
 Femoral head OA articular cartilage, altered biomechanical state of, 1028
 Fenopropfen, time course of response in juvenile rheumatoid arthritis, 1433
 Ferritin
 in early rheumatoid synovitis, 495
 in RA synovial fluid, 760
 Fertility in systemic sclerosis, 295
 Fetal loss, polymyositis/dermatomyositis and, 291
 Fever with malaise, in ant venom-treated RA, 277
 Fibrillation, immobilization, cartilage damage and, 208
 Fibrinolysis, plasminogen-dependent, by synovial fibroblasts, 664
 Fibroblasts
 canine synovial, hydroxyapatite stimulated ³H-thymidine in, 668
 dermal, in progressive systemic sclerosis and RA, 1144
 heterogeneity of, 174
 human foreskin, hydroxyapatite-stimulated thymidine uptake in 668
 human skin, intermediate filaments of in SLE, 922
 proliferation of, interleukin-1 and, 995
 in RA, 32, 857
 skin, CTAP-U and, 780
 Fibrocartilage, CPPD in, 789
 Fibromyalgia syndrome, primary, psychological factors in, 1101
 Fibronectin
 on articular cartilage surface in RA, 615
 inhibition of natural killer cell activity by, 838
 plasma, in rheumatic inflammatory disease, 913
 synovial fluid, in rheumatic inflammatory disease, 913
 Fibroplasia, α_2 -macroglobulin-proteinase complexes and, 897
 Fibrosis
 avian scleroderma and, 807
 basilar interstitial, in RA, 873
 dermal, in avian scleroderma, 807
 Fibrositis, primary, IgG at dermal-epidermal junction in, 1174
 Filaments, vimentin intermediate, in SLE, 922
 Fingers
 in acute calcific tendinitis of hand, 337

Fingers (*cont'd*)
 in POEMS syndrome, 1054
 in Raynaud's phenomenon, 139
 in scleroderma, platelet-inhibiting drugs and, 1137
 Fisher rats, adjuvant arthritis in, 682
 Flexion contractures in non-insulin-dependent diabetes, 960
 Flexor tendon of synovium, in carpal tunnel syndrome, 1192
 Focal glomerulonephritis in hydralazine-induced lupus, 822
 Follicle-stimulating hormone in adjuvant arthritis, 682
 Food and Drug Administration guidelines for clinical evaluation of drugs for rheumatic diseases, 1421
 Foot in RA, 1006
 Fractures, cervical, paraplegia and, complicating DISH, 472
 Free native type II collagen, type II collagen-induced arthritis in mice and, 1010
 FTS; *see* Thymuline
 Functional abnormalities, gross, in RA, 873
 Functional capacity, cost and outcome in RA and OA and, 522
 Functional status
 in RA, 864
 rehabilitation services and, 258
 Fungal hyaluronidase, glycosaminoglycan biosynthesis and, 1040

G

Galactosamine in human OA articular cartilage, 49
 Gas production in joint space in infectious arthritis, 960
 Gastrointestinal involvement
 anticentromere antibodies in PSS, 125
 azathioprine in RA and, 721
 penicillamine in RA and, 721
 Gelatin and metalloproteinase in rheumatoid synovial fluid, 285
 Genetics, joint inflammation and, in Down's syndrome, 929
 Geodes, intervertebral disc, hemodialysis and, 369
 Giant cell arteritis
 in Chinese patients, 120
 presenting as bilateral stroke, 819
 von Willebrand factor after glucocorticoids in, 1046
 Glomerulonephritis
 autoimmunity to collagen in MRL/l mice and, 313
 focal, in hydralazine-induced lupus, 822
 Glomerulus in hydralazine-induced lupus, 822
 Glomus tumor of hand, 449
 Glucocorticoids; *see also* Corticosteroids
 in giant cell arteritis, 1046
 Glucocorticoid-induced osteopenia, calcium and vitamin D for, 1336
 Glucosamine
 glycosaminoglycan biosynthesis by scleroderma fibroblasts and, 1040
 in human OA articular cartilage, 49
 Glutathione peroxidase in RA synovial fluid, 760
 Glycosaminoglycan synthesis

Glycosaminoglycan synthesis (*cont'd*)

- cartilage stress and, 675
- salicylates, indomethacin and, in canine knee cartilage, 398
- by scleroderma fibroblasts, 1040
- Gold sodium thiomalate
 - vs auranofin, 1346
 - IgM and IgM rheumatoid factor in RA after, 985
- Gold therapy; *see also* Aurothioglucose; Gold sodium thiomalate; Gold thioglucose; Sodium aurothiomalate
 - azathioprine and penicillamine after, in RA, 721
 - clinical response in RA, 985
 - HLA-DR antigens and, in RA, 601
 - nail pigmentation after, in RA, 119
 - neurotoxicity from auranofin, 1316
 - outcome assessment of, 1346
 - predictability of response to, 1210
 - second course, in RA, 1070
 - toxicity and HLA antigens, 601, 1215
- Gold thioglucose, predictability of response to, 1210
- Gout
 - in 101-year-old, 839
 - tophaceous, 468
- Granular lymphocytes, natural killer activity and, 1095
- Granulomatous arthritis in Crohn's disease, 1061
- Grip strength in RA, 267, 864
- Growth factor receptors, epidermal, in RA, 32
- Growth hormone in adjuvant arthritis in Fisher rats, 682
- Guinea pig studies of immobilization and cartilage damage, 208
- Guinea worm infestation, rheumatic syndromes secondary to, 694

H

- ³H thymidine, hydroxyapatite-stimulated in fibroblasts, 668
- Hand
 - in amyloid arthropathy, 457
 - in arthritis in Down's syndrome, 932
 - edema of, ketanserin and, in systemic sclerosis, 139
 - in RA, 1005
 - radiography of, in early RA, 744
 - renal osteodystrophy and, 1086
- Haplotypes of chromosome 6 in adult RA, 516
- ³H-DNA, CTAP-U and, 780
- ³H-dsDNA/anti-DNA immune complexes in SLE, 320
- Health status measure sensitivity, 1346
- Health status in RA and OA cost and outcome study, 522
- Heart
 - in avian scleroderma, 807
 - pregnancy in systemic sclerosis and, 295
 - tophus in mitral valve, 457
 - after total lymphoid irradiation in RA, 481
- Heat shock treatment, antibodies at chromosomal locus 93
 - after, in ankylosing spondylitis, 961
- Hemangioma of hand, 452
- Hematocrit, hemolysis, aspirin survival in vivo and, 422
- Hemoglobin in RA, 267
 - mast cells and, 845
 - penicillamine and, 721
- Hemolytic anemia, phosphofructokinase and, 116
- HEp-2 cells
 - anti-SS-A antibody staining by, 1318
 - in detecting ANA in juvenile rheumatoid arthritis, 1286
 - in myositis, 1150
- Hepatectomy, aspirin survival in vivo and, 422
- Hepatic veno-occlusive disease in SLE, 104
- Hepatotoxicity, aurothioglucose and, 230
- Hereditary angioedema, von Willebrand factor antigen levels in, 1405
- Herniated intervertebral disc, age-associated amyloid deposition in, 1063
- Herpes zoster after total lymphoid irradiation in RA, 481
- Hexuronate in cartilage in experimental OA, 391
- Hip, total arthroplasty, work disability before and after, 410
- Hip pain caused by cystic deformation of labrum acetabulare, 947
- Histiocytic lymphoma, diffuse, knee pain and spinal cord involvement in, 341
- HLA antigens
 - complement component abnormalities and, 1325
 - in knee joint arthritis, 1157
 - in RA and polymyalgia rheumatica, 1438
 - typing of, in Down's syndrome, 929
- HLA-A1 antigen
 - in multicentric reticulohistiocytosis, 344
 - B8, DR3 combination in RA, 833
- HLA-A2 antigen in knee joint arthritis, 1157
- HLA-A3 antigen and response to gold therapy, 1210
- HLA-B8 antigen in multicentric reticulohistiocytosis, 344
- HLA-B27 antigen
 - in ankylosing spondylitis, 361, 838, 1438
 - in juvenile ankylosing spondylitis, 698
 - in knee joint arthritis, 1157
 - in Reiter's syndrome, *Y. enterocolitica*, T cells and, 250
- HLA-Bw35 antigen, mucocutaneous lesions, and sodium aurothiomalate in RA, 833
- HLA-Bw44 antigen in arthritis of knee, 1157
- HLA-C4B alleles in scleroderma, 711
- HLA-DC genes in RA, 1206
- HLA-Dw antigen, RA and, 20
- HLA-DR antigens
 - gold toxicity and, in RA, 601
 - RA and, 20
 - in synovial membrane lymphocytes in RA, 32
- HLA-DR1 antigen
 - anticentromere antibodies and, in progressive systemic sclerosis, 125
 - in juvenile rheumatoid arthritis, 1281
 - in knee joint arthritis, 1157
- HLA-DR2 antigen
 - and Dw2 in RA, 20

- HLA-DR2 antigen (*cont'd*)
 gold toxicity and, 601
 in Sjögren's syndrome, 1245
- HLA-DR3 antigen
 gold toxicity and, in RA, 601
 in juvenile rheumatoid arthritis, 1281
 in Sjögren's syndrome, 1245
- HLA-DR4 antigen
 collagen autoimmunity and, 489, 1201
 gold therapy response and, 1210
 in RA, 1201, 1317
 and Dw4, 20
 rheumatoid factor and, 1215
- HLA-DR7 and DR8 antigens in knee joint arthritis, 1157
- HLA-DS antigen
 in Sjögren's syndrome, 1245
 in synovial membrane lymphocytes in RA, 32
- Hormones
 female, neutrophil responsiveness in vitro and, 623
 parathyroid, immunoreactive, prednisone and, in RA, 1050
 pituitary, adjuvant arthritis and, 682
- HTLV₁; *see* Human T cell leukemia virus
- Human adjuvant disease, cosmetic surgery and, 1
- Human autoantigens and NuMA protein, 774
- Human T cell leukemia virus (HTLV₁) in leukemia-associated arthritis, 1307
- Humoral immune response in collagen arthritis in Lewis rats, 797
- Humoral immunity and HLA-DR4 in RA, 489
- Hyaline cartilage erosions in RA, 968
- Hyaluronate in human OA articular cartilage, 49
- Hyaluronic acid
 glycosaminoglycan biosynthesis and, 1040
 in human OA articular cartilage, 49
 lubrication by synovial fluid and, 552
- Hyaluronidase
 digestion of, in OA articular cartilage, 49
 fibronectin on articular cartilage surface in RA and, 621
 fungal, glycosaminoglycan biosynthesis and, 1040
- Hydralazine-induced lupus, focal glomerulonephritis in, 822
- Hydrocortisone, chondrocyte proteinase release and, 79
- Hydrocortisone sodium succinate, lymphocyte-mediated cytotoxicity and, 72
- Hydrogen peroxide in RA synovial fluid, 760
- Hydrolase
 aspirin survival and, 422
 in cartilage, 186
- Hydrolysis, aspirin survival in vivo and, 422
- Hydroxyapatite crystals; *see* Calcium hydroxyapatite crystals
- Hydroxychloroquine for RA, 267, 1315
- Hypermobility of joints in Down's syndrome, 929
- Hyperostosis
 in the cervical spine, 564
 diffuse idiopathic skeletal; *see* Diffuse idiopathic skeletal
- Hyperostosis (*cont'd*)
 hyperostosis (DISH)
 sternocostoclavicular, cervical spine in, 567
- Hyperparathyroidism, secondary, dialysis, renal osteodystrophy and, 1086
- Hyperplasia, synovial cell, mitogenic effects of crystals in, 668
- Hyperplasia of liver, nodular regenerative, in POEMS syndrome, 1053
- Hypersensitivity, delayed, in collagen and adjuvant arthritis in Lewis rats, 803
- Hypertension
 intracranial, in Behçet's disease, 816
 malignant, in systemic sclerosis, 826
 pregnancy in systemic sclerosis and, 295
 pulmonary, anticentromere antibody and, 1075
- Hypertensive crises in systemic sclerosis, 826
- Hyperuricemia
 in the Marshall Islands, 713
 rheumatoid inflammation and, 443
- Hypochondriasis, SLE, RA and, 13
- Hypophysectomy in adjuvant arthritis in Fisher rats, 682
- Hypothyroidism after total lymphoid irradiation in RA, 481
- Hysteria, SLE, RA and, 13

I

- Ia antigens in sterile corneal ulceration in RA, 606
- Ibuprofen absorption and disposition in the elderly, 1066
- Idiopathic polymyositis in RA, 741
- IgA; *see also* Immunoglobulins
 lupus band test and, in detecting rheumatic diseases, 382
 in SLE, 638
- IgG; *see also* Immunoglobulins
 antibodies to, CTAP-U and, 780
 antibodies to dDNA in SLE, 132
 antibodies to native type II collagen in RA, 1370
 anticentromere antibodies and, 121
 anti-F(ab')₂ antibodies in juvenile arthritis and, 330
 autoantibodies to ribonucleoproteins, 238
 in avian scleroderma, 807
 in collagen arthritis in Lewis rats, 802
 at the dermal-epidermal junction in primary fibrositis, 1174
 human, C1 activation in RA and, 43
 IgM rheumatoid factor synthesis and, 502
 IgM rheumatoid factor and, 1130
 lupus band test and, in detecting rheumatic diseases, 382
 rheumatoid factor in MRL/l autoimmune mice, 1165
 in SLE, 638
 synthesis
 in RA, 754
 in rheumatoid synovium, 976
- IgM; *see also* Immunoglobulins
 antibodies to dDNA in SLE, 132
 antibodies to native type II collagen in RA, 1370

IgM (cont'd)

- anti-F(ab')₂ antibodies and, in juvenile arthritis, 330
- in avian scleroderma, 807
- lupus band test and, in detecting rheumatic diseases, 382
- pokeweed mitogen-induced, in RA, 985
- in RA, 737
- rheumatoid factor
 - CI activation and, 46
 - complement-mediated functions and, 1130
 - in MRL/l autoimmune mice, 1165
 - synthesis by RA cells, 502
- in SLE, 638
- Ig-positive cells in peripheral blood lymphocytes in RA, 991
- iliopectineal bursitis, inguinal swelling and, 239
- Immobilization, articular cartilage damage and, 208
- Immune adherence hemagglutination to determine CRI reactivity, 1329
- Immune complexes
 - anti-F(ab')₂ antibodies and, in juvenile arthritis, 330
 - complement-fixing dsDNA/anti-dsDNA, in SLE, 320
 - cutaneous polyarteritis nodosa and, 574
 - polymyalgia rheumatica and, 1107
 - in SLE, 1107
 - solubilization, IgM rheumatoid factor and, 1130
- Immune precipitation, IgM rheumatoid factor and, 1130
- Immune reactants in SLE, 631
- Immune response gene products in RA, 1201
- Immune system
 - α_2 -macroglobulin in RA and, 1122
 - regulation in SLE, 1095
- Immunofluorescence studies of IgG in primary fibrositis, 1174
- Immunogenetics, HLA-DR4 and collagen autoimmunity in RA, 489
- Immunoglobulins; *see also* IgA; IgG; IgM
 - anti-F(ab')₂ antibodies in juvenile arthritis and, 330
 - lupus band test and, in detecting rheumatic diseases, 382
 - in RA, 737
- Immunohistology of synovial membrane lymphocytes in RA, 32
- Immunologic abnormalities in Down's syndrome, 929
- Immunoreactive parathyroid hormone, prednisone in RA and, 1050
- Immunoregulation
 - in SLE, 1095
 - total lymphoid irradiation in RA and, 481
- In memoriam
 - Kunkel, Henry G., 356
 - Rodnan, Gerald P., 237
- Indomethacin in GAG and PGE₂ synthesis in canine knee cartilage, 398
- Infections
 - bacterial, after total lymphoid irradiation in RA, 481
 - bone, 454
 - Mycoplasma pulmonis*, arthritis in rats and, 943

Infectious arthritis

- enterococcus, 591
- gas production in joint space and, 960
- Inferior vena cava thrombosis in SLE, 539
- Inflammation
 - α_2 -macroglobulin-proteinase complexes and, 897
 - α_2 -macroglobulin in RA and, 1122
 - chronic, anti-F(ab')₂ antibodies and, 330
 - CTAP-III in, 663
 - in polymyalgia rheumatica, 1107
 - collagen type II and, 797
 - fibroblast heterogeneity and, 174
 - interleukin-1 and, 654
 - joint, α_2 -macroglobulin in RA and, 1122
 - labial salivary gland, in Sjögren's syndrome, 147
 - macrophages, interleukin-1 and, 995
 - pannus and, 956
 - rheumatoid, hyperuricemia and, 443
 - serum CIq, articular erosions and, in RA, 883
 - 6-sulfanilamidindazole-induced arthritis in rats and, 689
 - synovial, mast cells and, 841
 - wear particle-induced arthritis in rabbits and, 200
- Inflammatory alveolitis in scleroderma, 1254
- Inflammatory arthritis, collagen-induced, in Lewis rats, 797
- Inflammatory eye disease, 606
- Inflammatory joint disease, leukocyte elastase and, 905
- Inguinal swelling, iliopectineal bursitis and, 239
- Insulin, CTAP-U and, 780
- Interferon
 - acid labile α , in juvenile arthritis, 582
 - beta-2-microglobulin, autoimmune disease and, 358
 - in SLE, 597
- Interleukin-1
 - cytokine synthesis and, 88
 - fibroblast proliferation by, 995
 - gold sodium thiomalate in RA and, 989
- Interleukin-1-like factor, chondrocytes, synoviocytes and, 654
- Interleukin-2, autologous mixed lymphocyte response generation of, 1234
- Interphalangeal joint, renal osteodystrophy and, 1086
- Interstitial fibrosis, basilar, in RA 873
- Interstitial lung disease in scleroderma, 1254
- Intervertebral disc
 - hemodialysis and, 369
 - herniated, age-associated amyloid deposition in, 1063
- Intestine, small, in avian scleroderma, 807
- Intracranial hypertension in dural sinus thrombosis in Behçet's disease, 816
- Intraosseous tissue, mast cells in, 845
- Intravascular leukoaggregates, endothelial injury in SLE and, 631
- Iodoacetate, immobilization, cartilage damage and, 208
- Ir genes; *see* Immune response genes
- Iridocyclitis and ANA in JRA, 1286
- Iron in synovial fluid in early rheumatoid synovitis, 495

Ischemic digital ulcerations, ketanserin and, in systemic sclerosis, 139
Isoelectric focusing, IgG synthesis in RA and, 976

J

Jejunoileal bypass, rheumatoid arthritis and, 1300
Joint count in RA, 267
Joint disease
 in Down's syndrome, 929
 infectious, gas production in, 960
 inflammatory, leukocyte elastase and, 905
 lubrication by synovial fluid in, 552
 mast cells in, 852
 neuropathy, in POEMS syndrome, 1053
 osteoclasts and chondroclasts at erosion sites in, 968
 in progressive ankylosis of mice, 1411
 in RA, 737

 ant venom in, 277
 azathioprine for, 721
 CPPD crystal deposition and, 1002
 inflammation in, 277
 α_2 -macroglobulin and, 1122
 radiographic techniques in early disease and, 744
 serum C1q and erosions in, 883
 sexual functioning in, 217
 synovial membrane lymphocytes in, 37

Joints

α_2 -macroglobulin-proteinase complexes and synovitis in, 897

 changes of, in polymyalgia rheumatica, 1107
 in dracunculosis, 694

erosions

 renal osteodystrophy and, 1086
 serum C1q and, 883

 fibronectin on articular surface of, in OA, 615

 hypermobility of, in Down's syndrome, 929
 knee, 1157

 wear particle-induced arthritis in, of rabbits, 200

 mast cells in, 841

 metacarpophalangeal, 847

 narrowing of spaces of, in RA, 267

 rabbit, calcium phosphate clearance from, 427
 sacroiliac, 572

 sexual function and, in RA and ankylosing spondylitis, 217
 sternoclavicular, 1107

 swelling after total lymphoid irradiation, 481

 total hip arthroplasty and disability, 410

 trauma and, fibronectin on articular cartilage surface and, 615

Juvenile ankylosing spondylitis, aortic incompetence in, 698

Juvenile rheumatoid arthritis; *see also* Still's disease

 acid labile α -interferon in, 582

 ANA detected by HEP-2 cell substrate in, 1286

 anti-F(ab')₂ antibodies in, 330

 cervical spine in, 568

Juvenile rheumatoid arthritis (*cont'd*)

 CR1 diminished in, 1324

 cytotoxic anti-T cell antibodies in, 1273

 Down's syndrome and, 929

 HLA-DR in, 1281

 NSAID time course of response in, 1433

 in paintings of S. Botticelli, 1196, 1197

K

K562 target cells, natural killer activity and, 1095

Keratoacanthoma of hand, 450

Keratoconjunctivitis sicca

 artificial tears in, 459

 labial salivary gland and, in Sjögren's syndrome, 147

Ketanserin in Raynaud's phenomenon, 139

Kidney, SS-A/Ro antibody-antigen system and, 166

Knee

α_2 -macroglobulin-proteinase complexes and, 897

 arthritis of, 1157

 arthroscopic views of, 458

 cartilage, salicylates and indomethacin in GAG and PGE₂ synthesis, 398

 cartilage stress and, 675

 chondrocalcinosis in, 458, 1002

 chondroclasts and osteoclasts in RA in, 968

 CPPD in, in RA and OA, 1002

 in enterococcal arthritis, 591

 immobilization, cartilage damage and, 208

 lubrication by synovial fluid in, 552

 neutral protease and proteoglycans in, 305

 in polymyalgia rheumatica, 1107

 proteoglycan biosynthesis in experimental OA in, 388

 in RA, 458, 1006

 renal osteodystrophy and, 1086

 in wear particle-induced arthritis of rabbits, 200

Knee pain, spinal cord involvement in diffuse histiocytic lymphoma and, 341

Kunkel, Henry G. (In Memoriam), 356

L

Labial salivary gland in Sjögren's syndrome, 147

 biopsy of, 1320

 lactoferrin in, 462

Labrum acetabulare, hip pain caused by cystic deformation of, 947

Lacrimal gland in MRL/l and MRL/n mice, Sjögren's syndrome and, 157

Lactate-ammonia exercise test, 589

Lactobacillus casei cell wall-induced arthritis in LEW/N and F344/N rats, 939

Lactoferrin in Sjögren's syndrome, 462

Laryngeal involvement in RA, 873

Laryngoscopy, computerized tomography and, in RA, 873

Lectin, chondrocyte proteinase release and, 79

Lectin binding, chloroquine inhibition of mononuclear cell factor by, 888

Leg immobilization, articular cartilage damage and, 208

Leukemia

- arthritis in, 1306
- CR1 diminished in, 1324

Leukemia cells, monocytic, fibroblast proliferation by interleukin-1 from, 995

Leukoaggregates, intravascular, endothelial injury in SLE and, 631

Leukocyte elastase treatment, proteoglycan biosynthesis following, 905

Leukocytes, polymorphonuclear, in rheumatoid lesions, 857

Leukopenia, azathioprine in RA and, 721

Lewis rats

- collagen and adjuvant arthritis in, 797
- Mycoplasma pulmonis* infection and arthritis in, 943

LEW/N rats, *Lactobacillus casei* cell wall-induced arthritis in, 939

Life Events Inventory in primary fibromyalgia syndrome, 1101

Ligaments, posterior longitudinal, ossification of, 566

Lipid peroxidation, oxygen free radicals and, in RA synovial fluid, 760

Lipids in rheumatoid chyliform subcutaneous bursitis, 222

Lipopolysaccharides, anti-DNA antibodies in B6-+/+ mice and, 545

Lipoprotein cholesterol in RA and ankylosing spondylitis, 1199

Liver

- azathioprine in RA and, 721
- hepatotoxicity after aurothioglucose, 230
- in POEMS syndrome, 1055
- nodular regenerative hyperplasia of, 1053

Load-bearing, loss of in human femoral head OA articular cartilage, 1028

Low back pain in diagnosis of ankylosing spondylitis, 361

Lowe's syndrome, 357

Lumbar spine

- in ankylosing spondylitis, 361
- hemodialysis and, 369
- intervertebral disc in, 1064

Lung involvement

- in avian scleroderma, 807
- cystic lesions of in CREST syndrome, 929
- in scleroderma, 1254

Lung function in RA, 1218

Lupus; *see also* Systemic lupus erythematosus

- hydralazine-induced, focal glomerulonephritis in, 822

Lupus band test, clinical utility of, 382

Lupus erythematosus rash, bullous, Dapsone and, 1071

Luteinizing hormone in adjuvant arthritis in Fisher rats, 682

Lymphocyte activating factor, phenylglyoxal, thymocyte stimulating activity and, 654

Lymphocytes

- anti-DNA antibody synthesis in SLE and, 766

Lymphocytes (*cont'd*)

- in avian scleroderma, 807
- cytotoxicity and hydrocortisone, 72
- granular, natural killer activity and, 1085
- interleukin-1 and, 654
- in skin in progressive systemic sclerosis, 645
- synovial, in knee joint arthritis, 1157
- synovial membrane, in RA, 32
- total lymphoid irradiation and, 485

Lymphocytotoxic antibodies in JRA, 1272

Lymphocytotoxins in RA, 233

Lymphoid cells, α_2 -macroglobulin in RA and, 1122

Lymphoma

- diffuse histiocytic, knee pain and spinal cord involvement in, 341
- T cell, Sjögren's syndrome and, 951

Lymphopenia after total lymphoid irradiation in RA, 481

Lysosomal proteinase, cathepsin B and D in rheumatoid synovium and, 509

Lysozyme release, female hormones and, 623

M

Macrophages

- autologous mixed lymphocyte response in RA and, 1234
- Ia antigen-positive tissue, in sterile corneal ulceration in RA, 606
- inflammation, interleukin-1 and, 995
- in rheumatoid lesions, 857
- in skin in progressive systemic sclerosis, 645
- synovial, ferritin in, in rheumatoid synovitis, 495

Major histocompatibility complex, 6-sulfanilamidindazole-induced arthritis in rats and, 689

Malakoplakia, renal, in SLE, 704

Malalignment in early RA, 744

Malignancies

- distal phalangeal, 452
- reflex sympathetic dystrophy and, 1184

Malignant hypertension in systemic sclerosis, 826

Malignant lymphoma, T cell, in Sjögren's syndrome, 951

Malignant osseous neoplasms, distal phalangeal, 452

Mammoplasty, connective tissue disease after, 1440

Mast cells

- human synovial, in rheumatic diseases, 852
- in RA, 845
- in rheumatoid lesions, 857
- synovial inflammation and, 841

Mastocytosis, articular, in RA, 845

Matrix rupture of human femoral head OA articular cartilage, 1028

Meniscal tear, 458

Menisci, biosynthetic activity in, in experimental OA, 388

Metacarpophalangeal joint, renal osteodystrophy and, 1086

Metachromasy in wear particle-induced arthritis in rabbits, 200

Metalloproteinases; *see also* Proteinase

- Metalloproteinases** (*cont'd*)
 proteoglycans and, in cartilage, 305
 in rheumatoid synovial fluid, 285
- Metastatic tumors**, 452
- Methimazole** in antithyroid arthritis syndrome, 227
- Methotrexate**
 in psoriatic arthritis, 376
 in RA, 599
- Minnesota Multiphasic Personality Inventory**
 in primary fibromyalgia syndrome, 1101
 in RA and SLE, 13
- Mitogen responses after total lymphoid irradiation in RA**, 486
- Mitogenic effect of hydroxyapatite and CPPD crystals**, 668
- Mitotic cells**, NuMA protein and, 774
- Mitral valve**, tophus in, 457
- Mixed connective tissue disease**; *see also* Connective tissue disease
 pneumatosis intestinalis in, 1186
 prognosis of, 596
- Monoclinic calcium pyrophosphate dihydrate (CPPD) deposition**, gelatin model of, 789
- Monoclonal antibodies**
 to CR1, 1329
 in leukemic cell identification in synovial fluid, 1306
 sterile corneal ulceration in RA and, 606
 synovial membrane lymphocytes in RA and, 32
- Monoclonal anti-DNA antibodies in B6-lpr/lpr mice**, 545
- Monoclonal anti-type II collagen antibodies**, collagen-induced arthritis in mice and, 1010
- Monoclonal B cell activation**, monoclonal proteins and, in SLE, 638
- Monoclonal proteins**
 in POEMS syndrome, 1053
 in SLE, 638
- Monocytes**
 chloroquine inhibition of mononuclear cell fraction and, 888
 chondrocyte proteinase release and, 79
 IgM in RA and, 985
- Monocytic leukemia cells**, fibroblast proliferation by interleukin-1 from, 995
- Mononuclear cell-derived mediators**, fibroblast heterogeneity and, 174
- Mononuclear cell factor**, chloroquine inhibition of, 888
- Mononuclear cell infiltrates**
 in avian scleroderma, 807
 in MRL/l and MRL/n mice, Sjögren's syndrome and, 157
- Mononuclear cells**
 α_2 -macroglobulin-proteinase complexes and, 897
 collagenase production by, 1397
 fibroblast heterogeneity and, 174
 gold salts and, in RA, 985
 natural killer activity and, 1095
 penicillamine and, in RA, 985
 IgM rheumatoid factor synthesis by RA cells and, 502
- Mononuclear cells** (*cont'd*)
 in RA, myositis and, 737
 in skin in progressive systemic sclerosis, 645
 total lymphoid irradiation in RA and, 486
- Mononucleosis virus**, acute arthritis and, 240
- Monosodium urate (MSU) crystals**, nuclide uptake and, 668
- Morbidity in RA**, 481
 after total lymphoid irradiation, 481
- Morning stiffness in RA**, 267
 after total lymphoid irradiation, 481
- Mortality in RA**, 864
 after total lymphoid irradiation, 481
- Mouse studies**; *see also* B6-+/+ mice; B6-lpr/lpr mice; Balb/c mice; C57BL/6J mice; C57BL/6J-lpr/lpr mice; CBA/J mice; CD/1 Swiss mice; DBA/2 mice; MRL/l mice; MRL/n mice; NZB mice; PN mice
 colchicine inhibition of SAA, 349
 polymyositis induced by coxsackievirus B1, 433
- MRL/l mice**
 autoimmune, IgG rheumatoid factor in, 1165
 collagen autoreactivity in, 313
 Sjögren's syndrome in, 157
- MRL/n mice**
 collagen reactivity in, 313
 Sjögren's syndrome in, 157
- MS phenotypes**, small airways function in RA and, 728
- MT2 in Sjögren's syndrome**, 1245
- MT3 specificity in RA**, 20, 1201
- MT4 determinant in RA**, 1201
- Mucocutaneous lesions**, HLA-Bw35, sodium aurothiomate and, in RA, 833
- Mucosal abnormalities in RA**, 873
- Multicentric reticulohistiocytosis**, primary biliary cirrhosis and, cytotoxic agents in, 344
- Murine lupus**, collagen autoreactivity in, 313
- Muscle**, sarcoplasmic reticulum dysfunction in polymyositis and, 299
- Muscle biopsy for myoadenylate deaminase deficiency in PSS**, 586
- Muscle fiber necrosis in RA**, 737
- Muscle weakness**
 coxsackievirus B1 (Tucson strain) induced in mice and, 433
 sarcoplasmic reticulum in polymyositis and, 299
- Musculoskeletal examinations**, patient models for, 557
- Myalgia**, von Willebrand factor and, 1046
- Myasthenia gravis**, optic neuritis, transverse myelitis, and anti-DNA antibodies in, 701
- Mycobacterium tuberculosis** in collagen arthritis in Lewis rats, 797
- Mycoplasma pulmonis** infection, arthritis in Lewis rats and, 943
- Myelitis**, transverse
 in myasthenia gravis, 701
 in SLE, 1058
- Myoadenylate deaminase deficiency in progressive systemic sclerosis**, 586

- Myocardial infarction after total lymphoid irradiation in RA, 481
- Myopathy, noninflammatory, in progressive systemic sclerosis, 586
- Myositis
 - coxsackievirus B1 (Tucson strain) induced in mice, 433
 - in RA, 737
 - sera, antibodies in, 1150

N

- Nail pigmentation after gold therapy in RA, 119
- Nailfold biopsy
 - in connective tissue diseases, 97
 - in scleroderma, 97
- Nailfold capillary patterns, 458
- Native DNA in SLE, 132
- Natural killer cells
 - hydrocortisone sodium succinate and, 72
 - inhibition of by fibronectin, 838
 - in SLE, 1072
- Natural killer cytotoxic factor, soluble, in SLE, 1095
- Natural thymocytotoxic antibody, testing for, 599
- Necrosis, aseptic, in pancreatitis, 1309
- Neoplasms
 - benign osseous, of hand, 450
 - malignant osseous, distal phalangeal, 452
- Nephropathy
 - chemotherapy-induced acute uric acid, piroxicam and, 116
 - HLA-Bw35, mucocutaneous lesions, and aurothiomalate in RA, 833
- Nephrotic syndrome, thrombosis in SLE and, 539
- Neuritis, optic, in myasthenia gravis, 701
- Neuroarthropathy in POEMS syndrome, 1053
- Neurologic findings in SLE with transverse myelitis, 1059
- Neurologic involvement in giant cell arteritis presenting as bilateral stroke, 819
- Neuropathic joint disease in POEMS syndrome, 1053
- Neurotoxicity from auranofin, 1316
- Neutral proteases, proteoglycans and, in cartilage, 305
- Neutropenia in SLE, 719
- Neutrophil aggregating activity in SLE, 631
- Neutrophil responsiveness in vitro, female hormones and, 623
- Neutrophils
 - α_2 -macroglobulin-proteinase complexes and, 897
 - female hormones and, 623
 - in SLE, 631
- Nifedipine in Raynaud's phenomenon, 959
- Nodular regenerative hyperplasia of liver in POEMS syndrome, 1053
- Nodules, rheumatoid, rheumatoid chyliform bursitis and, 221
- Nonsteroidal antiinflammatory drugs (NSAID)
 - compliance with by RA patients, 1227
- Nonsteroidal antiinflammatory drugs (NSAID) (*cont'd*)
 - in Down's syndrome, 929
 - FDA guidelines for evaluation of, 1421
 - in JRA, time course of response to, 1433
 - lipoprotein cholesterol, apoprotein A-I and, in RA and ankylosing spondylitis, 1199
 - methotrexate and, in psoriatic arthritis, 376
- Notch root, in biomechanics of human femoral head OA articular cartilage, 1028
- NTP; *see* Nucleoside triphosphate
- Nuclear antigens, autoantibodies to, in MRL/l mice, 1165
- Nuclear mitotic apparatus (NuMA) protein, 774
- Nuclear proteins, speckled antinuclear antibodies as, 92
- Nucleoside triphosphate (NTP) pyrophosphohydrolase in cartilage, 186, 193
- Nucleotides
 - cyclic, in progressive systemic sclerosis and RA, 1144
 - in SLE, 706
- NuMA protein, 774
- NZB/NZW mice, Sjögren's syndrome and, 157

O

- Obesity and osteoporotic fractures, 1353
- Ocular epithelial surface antigens in sterile corneal ulceration in RA, 606
- OKT8 monoclonal antibody, suppressor T cells and, in RA with vasculitis, 752
- Oligoclonal serum IgG in RA, 976
- Optic neuritis in myasthenia gravis, 701
- Oral angiotensin converting enzyme inhibitor MK 421, in systemic sclerosis, 826
- Organomegaly in POEMS syndrome, 1053
- Orthorhombic calcium pyrophosphate tetrahydrate (o-CPPT), gelatin model of, 789
- Osseous neoplasms
 - benign, of hand, 450
 - malignant, distal phalangeal, 452
- Ossification
 - in cervical spine, 564, 570
 - posterior longitudinal ligament, cervical spine in, 566
- Osteitis condensans ilii, sacroiliitis and, 357
- Osteoarthritis; *see also* Degenerative joint disease
 - articular cartilage in, 49
 - biomechanical state of femoral head in, 1028
 - neutral proteases and proteoglycans in, 305
 - cartilage, NTP pyrophosphohydrolase in, 186, 193
 - cost and outcome in, 522
 - CPPD in knee in, 1002
 - fibronectin, articular cartilage and, 615
 - proteoglycans in cartilage and, 305
 - synovial fluid fibronectin in, 913
 - synovial membrane lymphocytes and, 32
 - in thalassemia minor, 1076
 - wrist and, 1191
 - zinc in, 1073

Osteoarthropathy, erosive azotemic, 1086
 Osteoclasts
 at subchondral erosion sites in rheumatoid joints, 968
 mast cells and, in RA, 845
 Osteodystrophy, renal, erosions in, 1086
 Osteoid, mast cells and, in RA, 845
 Osteoid osteoma of hand, 451
 Osteomyelitis, distal phalangeal, 454
 Osteopenia induced by glucocorticoids, treatment for, 1336
 Osteophytes
 immobilization, cartilage damage and, 208
 in knee joint in wear particle-induced arthritis in rabbits, 205
 Osteophytosis, CPPD in RA and, 1002
 Osteoporosis
 and fractures in RA, 1346
 trabecular, mast cells and, 845
 Outcome assessment in clinical trials, 1346
 Outpatient visits, cost and outcome in RA and OA, 522
 Oxygen free radicals in RA synovial fluid, 760

P-Q

Pain
 chronic, in primary fibromyalgia syndrome, 1101
 hip, caused by cystic deformation of labrum acetabulare, 947
 of the joint
 ant venom and, in RA, 277
 work disability, total hip arthroplasty and, 410
 knee, in histiocytic lymphoma, 341
 in lumbar spine and ankylosing spondylitis, 361
 risk of ankylosing spondylitis and, 241
 shopping bag syndrome and, 719
 transcutaneous electronic nerve stimulation (TENS) and, 1074
 Pancreas, adenocarcinoma of, and reflex sympathetic dystrophy, 1183
 Pancreatitis
 aseptic necrosis and calcaneal insufficiency fractures in, 1309
 in SLE, 118
 Pannus
 cell types in, 857
 extraosseous, mast cells in, 845
 hyaline cartilage destruction and, in RA, 968
 inflammation and, 956
 in RA, 957
 Pannus extension, fibronectin on articular cartilage surface in RA and, 615
 Parakeratosis, nailfold biopsy in connective tissue disease and, 97
 Paraneoplastic syndrome and reflex sympathetic dystrophy, 1183
 Paraplegia, cervical fracture and, complicating DISH, 472
 Paraproteinemia in SLE, 638

Parathyroid hormone
 effect of glucocorticoids on, 1336
 immunoreactive, prednisone and, in RA, 1050
 Parotid gland in Sjögren's syndrome, 147
 T cell lymphoma and, 951
 Patient assessment in RA, 267
 Patient instructors in teaching and assessing rheumatology care, 557
 Pauciarticular arthritis
 in Down's syndrome, 929
 heart and, in juvenile ankylosing spondylitis, 698
 Penicillamine for RA, 267, 840, 1315
 compliance with, 1229
 after gold, 721
 IgM and IgM rheumatoid factor after, 985
 lung function and, 1223
 pharmacokinetics correlated with clinical effects of, 1362
 Peptidase, wear particle-induced arthritis in rabbits and, 200
 Peptides in synovial fluid fibronectin, 913
 Peptidoglycans, chloroquine inhibition of mononuclear cell factor and, 888
 Periarthritis, confusion with acute calcific tendinitis of hand, 330
 Perinatal deaths, polymyositis/dermatomyositis and, 291
 Peripheral blood mononuclear cells
 chloroquine inhibition of mononuclear cell factor and, 888
 fibroblast heterogeneity and, 176
 gold salts and, in RA, 985
 IgM rheumatoid factor synthesis by RA cells and, 502
 natural killer activity and, 1095
 penicillamine and, in RA, 985
 Pharmaceutical industry, rheumatology practice and, 1079
 Phenylglyoxal, lymphocyte activating factor, thymocyte-stimulating activity, 654
 Phosphatase, alkaline
 prednisone and, in RA, 1050
 renal osteodystrophy and, 1086
 Phosphate in proteoglycan of human articular cartilage, 58
 Phosphoamino acid analysis of proteoglycans, 1025
 Phosphoamino acids in proteoglycan of human articular cartilage, 67
 Phosphofructokinase, hemolytic anemia and, 116
 Phosphoproteins in human articular cartilage, 58
 Phosphoproteoglycans, human articular cartilage and, 58
 Phosphorus, prednisone and, in RA, 1050
 Phosphorylation of proteoglycans by cAMP-dependent protein kinase, 1023
 Phosphoserine in human articular cartilage, 58
 Physiotherapy, compliance with, in RA patients, 1227
 Phytohemagglutinin, total lymphoid irradiation in RA and, 486
 Piroxicam, chemotherapy-induced acute uric acid nephropathy and, 116
 Pituitary hormones, adjuvant arthritis and, 682
 Plasma cells
 in polymyalgia rheumatica, 1113

- Plasma cells (*cont'd*)
in rheumatoid lesions, 857
- Plasma fibronectin in rheumatic inflammatory disease, 913
- Plasma renin activity, platelet-inhibiting drugs in scleroderma and, 1137
- Plasmacytic dyscrasia, SLE and, 638
- Plasminogen activator
human interleukin-1 and, 654
synovial fibroblasts, CTAP-III and, 663
wear particle-induced arthritis in rabbits and, 200
- Platelet-inhibiting drugs in scleroderma, 1137
- Platelets, dipyridamole and aspirin in scleroderma and, 1137
- Plethysmography, cold challenge in systemic sclerosis and, 139
- PN mice, Sjögren's syndrome and, 157
- Pneumatoxis in mixed connective tissue disease, 1186
- Pneumoperitoneum in mixed connective tissue disease, 1186
- Pneumothorax in CREST syndrome, 935
- POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal [M-] protein, and skin changes) syndrome, 1053
- Pokeweed mitogen
cytokines, chondrocyte proteinase release and, 85
IgM rheumatoid factor synthesis by RA cells and, 502
- Pokeweed mitogen-driven IgG and anti-DNA antibody synthesis, 767
- Pokeweed mitogen-induced IgM rheumatoid factor in RA, 985
- Poly(dT), poly I in SLE, 132
- Polyarthritis nodosa, cutaneous, progressive arthritis and, 574
- Polyarthritis
chronic, in rats, 939
in multicentric reticulohistiocytosis, 344
- Polyarticular arthritis in Down's syndrome, 929
- Polychondritis, relapsing, 457
- Polyclonal antibodies in leukemic cell identification in synovial fluid, 1306
- Polyclonal anti-type II collagen antibody, collagen-induced arthritis in mice and, 1010
- Polyclonal B cell activators, α_2 -macroglobulin in RA and, 1122
- Polymorphonuclear leukocytes
proteoglycan biosynthesis and, 905
in rheumatoid lesions, 857
- Polymyalgia rheumatica
HLA antigen frequencies in, 1438
metastatic renal cell carcinoma and, 116
synovitis in, 1107
von Willebrand factor in, 1046
- Polymyositis
antibodies in, 1150
cosmetic surgery and, 1
dysfunction of sarcoplasmic reticulum in, 299
idiopathic, in RA, 741
induced by coxsackievirus B1 in mouse, 433
- Polymyositis/dermatomyositis, pregnancy and, 291
- Polyneuropathy in POEMS syndrome, 1053
- Polynucleotides, anti-DNA antibodies in B6-lpr/lpr mice and, 545
- Popliteal cysts, anterior tibial mass and, 113
- Posterior longitudinal ligament, ossification of, cervical spine in, 566
- Precipitin interactions in MRL/l mice, 1165
- Prednisone, low-dose, in RA, vitamin D metabolism and, 1050
- Pregnancy
polymyositis/dermatomyositis and, 291
systemic sclerosis and, 295
Wegener's granulomatosis
onset after, 1314
onset during, 109
- Premature infants
polymyositis/dermatomyositis and, 291
pregnancy in systemic sclerosis and, 295
- Primary biliary cirrhosis, multicentric reticulohistiocytosis and, cytotoxic agents in, 344
- Primary epidermoid carcinoma, distal phalangeal, 452
- Primary fibromyalgia syndrome, psychological factors in, 1101
- Primary fibrositis, IgG at dermal-epidermal junction in, 1174
- Private rheumatology practice, 359
- Progesterone, neutrophil responsiveness in vitro and, 623
- Progressive ankylosis of mice, calcium hydroxyapatite deposition in, 1411
- Progressive systemic sclerosis; *see also* Scleroderma; Systemic sclerosis
anticentromere antibodies in, 125
cAMP and calcium transport in, 1144
clinical characteristics of, 648
conjugal, 1180
cosmetic surgery and, 1
criteria for, 126
familial, 1181
glycosaminoglycan biosynthesis and, 1040
lymphocytes in skin in, 645
myoadenylate deaminase deficiency in, 586
Sjögren's syndrome and, 1245
SS-B antibodies and glandular fibrosis in, 478
- Prolactin in adjuvant arthritis in Fisher rats, 682
- Properdin, lupus band test and, in detecting rheumatic diseases, 382
- Propranolol, calcium transport and, in progressive systemic sclerosis and RA, 1144
- Propylthiouracil in antithyroid arthritis syndrome, 227
- Prostaglandin E, human interleukin-1 and, 654
- Prostaglandin E₂ synthesis
fibroblast heterogeneity and, 174
salicylates, indomethacin and, in canine knee cartilage, 398
- Prostaglandins
chloroquine inhibition of mononuclear cell factor and, 888

Prostaglandins (cont'd)

Perls' ferric iron and, in rheumatoid synovitis, 495

Protease

CTAP-U and, 780

neutral, proteoglycans and, in articular cartilage, 305

trypsin-like, α_2 -macroglobulin in RA and, 1122

Protein

in human articular cartilage, 58

lubrication by synovial fluid and, 552

lupus band test and detection of in rheumatic disease, 382

monoclonal, in SLE, 638

monoclonal (m-), in POEMS syndrome, 1053

nailfold biopsy in connective tissue diseases and, 97

nuclear, speckled antinuclear antibodies as, 92

NuMA, 774

in Perls' positive iron in rheumatoid synovitis, 495

phosphorylation of proteoglycans from cartilage and, 1023
synthesis

cartilage stress and, 675

colchicine and, 349

in mouse liver cell cultures, 349

Protein band, vimentin intermediate filaments in SLE and, 922

Proteinase; see also Metalloproteinase

α_2 -macroglobulin, synovitis and, 897

cathepsin B in rheumatoid synovium, 509

cytokine modulation of, 79

in wear particle-induced arthritis in rabbits, 202

Proteinuria

Bence Jones, SLE and, 638

HLA-DR3 antigen and, in RA, 601

penicillamine in RA and, 721

Proteoglycans

biosynthesis of

after elastase treatment, 905

in knee in experimental OA, 388

cytokines, chondrocyte proteinase release and, 84

degradation, leukocyte elastase and, 905

fibronectin on articular cartilage surface in RA and, 615

in human OA articular cartilage, 49

leukocyte elastase and, 905

metalloproteinase and, in rheumatoid synovial fluid, 285

neutral proteases and, in articular cartilage, 305

phosphoamino acid analysis of, 1025

phosphorylation of by cAMP-dependent protein kinase, 1023

human articular cartilage and, 58

Proximal interphalangeal joint, renal osteodystrophy and, 1086

Pruritis

local, in ant venom-treated RA, 277

penicillamine in RA and, 721

Pseudoleukocytosis, essential mixed cryoglobulinemia and, 353

***Pseudomyrmex* sp. ant venom in RA, 277**

Psoriatic arthritis

methotrexate in, 376

zinc in, 1073

Psoriatic spondylitis, cervical spine in, 564

Psychological factors in primary fibromyalgia syndrome, 1101

Pulmonary function

in RA, 728, 1218

in scleroderma, 1254

Pulmonary hypertension, anticentromere antibody and, 1075

Pulmonary involvement, anticentromere antibodies and in PSS, 125

Pulse methylprednisolone in subacute cutaneous SLE, 837

Purified protein derivative, total lymphoid irradiation in RA and, 486

Purine metabolic pathways, 588

Purine nucleoside triphosphate, cartilage NTP pyrophosphohydrolase and, 404

Pyrimidine nucleoside triphosphate, cartilage NTP pyrophosphohydrolase and, 404

Pyrophosphatase, NTP pyrophosphohydrolase in cartilage and, 186

Pyrophosphate, ectoenzymes and, 404

Pz-peptidase, wear particle-induced arthritis in rabbits and, 200

Quality of life, rehabilitation services and, 262

R

Rabbit studies

α_2 -macroglobulin-proteinase complexes, 897

proteoglycan biosynthesis following leukocyte elastase, 905

⁸⁵Sr-labeled calcium phosphate crystal clearance, 427
wear-induced arthritis, 200

Radiography

of craniocervical region in RA, 26

in early RA, 744

Rash

bullous lupus erythematosus, Dapsone and, 1071

penicillamine in RA and, 721

photosensitivity, in SLE, 458

Rat chondrosarcoma, phosphorylation of proteoglycans from, 1023

Rat studies; see also Fisher rats; LEW/N rats; Lewis rats

Lactobacillus casei cell wall-induced arthritis, 939

6-sulfanilamidindazole-induced arthritis, 689

Rate electrophoresis, α_2 -macroglobulin-proteinase complexes and, 897

Raynaud's phenomenon

anticentromere antibodies in, 121

ketanserin in, 139

nailfold biopsy in, 97

nifedipine in, 959

Reactants, immune, in SLE, 631

Reactive arthritis, T cells, *Yersinia enterocolitica* in Reiter's syndrome and, 250

- Receptors for complement in SLE, 1321
- Red blood cells, complement-fixing dsDNA/anti-dsDNA immune complexes in SLE and, 320
- Reflex sympathetic dystrophy as paraneoplastic syndrome, 1183
- Regenerative hyperplasia of liver, nodular, in POEMS syndrome, 1053
- Rehabilitation services for the homebound elderly, 258
- Rehabilitative rheumatology in rheumatology education, 1076
- Reiter's syndrome
knee joint arthritis in, 1157
Yersinia enterocolitica, T cells and, 250
- Relapsing polychondritis, 457
- Renal biopsy, in SLE, 704
- Renal cell carcinoma, metastatic, polymyalgia rheumatica and, 116
- Renal failure, renal malakoplakia and, in SLE, 704
- Renal function in systemic sclerosis, 826
- Renal involvement
in avian scleroderma, 807
in hydralazine-induced lupus, 822
osteodystrophy and joint erosions, 1086
in SLE, 132
malakoplakia in, 704
in systemic sclerosis, 826
- Renal vein thrombosis in SLE, 539
- Reserpine for digital ulcers in systemic sclerosis, 1314
- Respiratory failure in CREST syndrome, 935
- Reticular skin discoloration in primary fibrositis, 1174
- Reticulohistiocytosis, multicentric, primary biliary cirrhosis and cytotoxic agents in, 344
- Rheumatic diseases
apheresis and, 1081
human synovial mast cells in, 852
lupus band test in detection of, 382
zinc in, 1073
- Rheumatic inflammatory disease, synovial fluid fibronectin in, 913
- Rheumatic syndromes secondary to guinea worm infestation, 694
- Rheumatoid activity index, serum uric acid and, 443
- Rheumatoid arthritis
 α_2 -macroglobulin in, 1122
 α_2 -macroglobulin-proteinase complexes and, 897
androgen levels in men with, 958
angiotensin converting inhibitors in, 840
ant venom in, 277
anticollagen antibodies in, 1201
anti-IgG antibodies in, 1382
apheresis in, 1083
apoprotein A-I in, 1199
articular erosions and serum C1q in, 883
articular mastocytosis in, 845
- Rheumatoid arthritis (*cont'd*)
autologous mixed lymphocyte response in, 1234
azathioprine and penicillamine after gold in, 721
B cells in, 985
bacterial infection after total lymphoid irradiation in, 481
basilar interstitial fibrosis in, 873
button test in, 864
C1 absence in, 40
cAMP and calcium transport in, 1144
cardiorespiratory arrest after total lymphoid irradiation in, 481
cartilage destruction by pannus in, 956, 957
chloroquine inhibition of mononuclear cell factor and, 888
chyliform bursitis, rheumatoid nodules and, 221
circulating immune complexes and C1 in, 40
clinical characteristics of, 607
complement in, 737
compliance with therapy in, 1227
computed tomography of craniocervical region in, 26, 1439, 1440
concanavalin A and total lymphoid irradiation in, 481
cosmetic surgery and, 1
costs and outcome in, 522
CPPD crystal deposition in, 1002
CR1 diminished in, 1324
creatinine phosphokinase in, 737
cricoarytenoid arthritis and, 873
cutaneous vasculitis after total lymphoid irradiation in, 481
difficulty during inspiration in, 873
disease activity in, ant venom and, 279
drug therapy in, 864
early, radiographic evaluation of, 744
erosions in, 267
erosive, serum C1q and, 883
erythrocyte sedimentation rate in, 267, 279
synovitis and, 737
fibronectin on articular cartilage surface in, 615
foot in, 1006
fracture risk in, 1353
functional abnormalities in, 873
functional status in, 864
gold therapy for
predictability of response to, 1210
second course of, 1070
grip strength in, 267, 864
hand in, 1005
haplotypes of chromosome 6 in, 516
 ^3H -dsDNA/anti-DNA immune complexes in, 320
helper T cells (T4) after total lymphoid irradiation in, 481
hemoglobin in, 267
herpes zoster after total lymphoid irradiation in, 481
HLA antigen frequencies in, polymyalgia and, 1438
HLA-Bw35, mucocutaneous lesions and aurothiomalate in, 833

Rheumatoid arthritis (*cont'd*)

- HLA-DR antigens and, 20
- gold toxicity in, 601
- HLA-DR4 and, 1201, 1317
 - collagen autoimmunity in, 489
- HLA-DR4/Dw4 and HLA-DR2/Dw2 in, 20
- HLA-Dw and, 20
- hydroxychloroquine in, 267, 1315
- hypothyroidism after total lymphoid irradiation in, 481
- IgG and IgM antibodies to native type II collagen in, 1370
- IgG synthesis in, 754, 976
- IgM rheumatoid factor synthesis in, 502
- immune response gene products in, 1201
- immunoglobulin in, 737
- immunoregulation after total lymphoid irradiation in, 481
- inflammation, hyperuricemia and, 443
- jejunoileal bypass and, 1300
- joint count in, 267
- joint disease in, 737
 - chondroclasts and osteoclasts in, 968
 - narrowing in, 267
 - pain in, 277
 - swelling in, 277
 - total lymphoid irradiation and, 481
- knee in, 458, 1006, 1157
- laryngeal involvement in, 873
- lesions, histopathology of, 857
- lipoprotein cholesterol in, 1199
- lymphocyte phenotypes and total lymphoid irradiation in, 481
- lymphocytotoxins and, 233
- lymphopenia after total lymphoid irradiation in, 481
- mast cells in, 845
- methotrexate in, 599
- mitogen responses after total lymphoid irradiation in, 486
- mononuclear cell infiltration and myositis in, 737
- morbidity in, 864
 - after total lymphoid irradiation, 481
- morning stiffness in, 267
 - after total lymphoid irradiation, 481
- mortality in, 864
 - after total lymphoid irradiation, 481
- MRL/l autoimmune mice and, 1165
- mucosal abnormalities in, 873
- muscle involvement in, 737
- myocardial infarction after total lymphoid irradiation in, 481
- myositis in, 737
- nail pigmentation after gold therapy in, 119
- nodules and chyliform bursitis in, 221
- osteoclasts and chondroclasts in knee in, 968
- patient assessment in, 267
- penicillamine in, 267, 840, 1315
 - pharmacokinetics of, correlated with clinical effects, 1362
- phytohemagglutinin and total lymphoid irradiation in, 486

Rheumatoid arthritis (*cont'd*)

- pokeweed mitogen-induced IgM and IgM rheumatoid factor in, 985
 - polymyositis, idiopathic in, 741
 - prednisone and vitamin D metabolism in, 1050
 - psychological factors in, 1101
 - psychosocial impact of, 13
 - purified protein derivative and total lymphoid irradiation in, 486
 - radiography of craniocervical region in, 26
 - refractory, total lymphoid irradiation in, 481
 - rheumatoid factor in, 267, 755
 - in myositis, 737
 - sexuality in, 217
 - Sjögren's syndrome in, 1245
 - small airways function and, 728, 1218
 - sore throat in, 873
 - spinal cord compression in, 26
 - sterile corneal ulceration and, 606
 - streptokinase-streptodornase and total lymphoid irradiation in, 486
 - structural lesions in, 873
 - sulfhydryl compounds in, 840
 - synovial fluid
 - fibronectin in, 913
 - oxygen free radicals and H₂O₂ in, 760
 - synovial membrane
 - lymphocytes in, 32
 - mast cells in, 845
 - synovitis in
 - ESR and, 737
 - synovial iron and, 495
 - synovium in
 - cathepsin B in, 509
 - IgG synthesis in, 976
 - T cells in, 32
 - thalidomide in, 1118
 - thiotepea and corticosteroids in, 864
 - thymidine incorporation and total lymphoid irradiation in, 486
 - thymuline in, 117
 - tooth loss after total lymphoid irradiation in, 481
 - with vasculitis, suppressor T cells in, 752
 - vocal cords in, 873
 - von Willebrand factor antigen levels in, 1405
 - walking time in, 864
 - after total lymphoid irradiation, 481
 - weight loss after total lymphoid irradiation in, 481
 - work disability in, 864
 - xerostomia after total lymphoid irradiation in, 481
 - zinc in, 1073
- Rheumatoid arthritis nuclear antigen (RANA)
- Epstein-Barr virus and, 476
 - polymorphism of, 1423
- Rheumatoid factor
- CI activation and, in RA, 46

Rheumatoid factor (*cont'd*)
 complement-mediated functions and, 1130
 gold therapy response and, 1215
 HLA-DR4 and, 1215
 IgM and, in rheumatoid myositis, 737
 in MRL/l autoimmune mice, 1165
 pokeweed mitogen-induced, in RA, 1118
 in RA, 267, 752
 thalidomide and, 1118
 rheumatoid myositis and, 737
 Rheumatology care, patient instructors in, 557
 Rheumatology education
 patient instructors in, 557
 rehabilitation training in, 1076
 Rheumatology practice, private, 359
 Ribonucleoproteins
 antibodies to, 238
 IgG autoantibodies to, 238
 RNA
 in SLE, 132
 synthesis, chondrocyte proteinase release and, 79
 Ro antigen, tissue substrate and, 166
 Rodnan, Gerald P. (In Memoriam), 237

S

Sacroiliac joint
 in DISH in ankylosing spondylitis, 572
 renal osteodystrophy and, 1089
 Sacroiliitis, 596
 in ankylosing spondylitis, 361
 osteitis condensans ilii and, 357
 risk of and HLA-B27, 241
 Salicylates; *see also* Aspirin
 in GAG and PGE₂ synthesis in canine knee cartilage, 398
 Salivary gland in Sjögren's syndrome
 lactoferrin in, 462
 in MRL/l and MRL/n mice, 157
 Salivary gland biopsy in Sjögren's syndrome, 147
 Sarcoplasmic reticulum, dysfunction of, in polymyositis, 299
 Sciatica, hip pain, deformed cartilaginous labrum and, 947
 Scleroderma; *see also* Progressive systemic sclerosis; Systemic sclerosis
 avian, mononuclear cell infiltrates in, 807
 C4B alleles and, 711
 conjugal, 1180
 cosmetic surgery and, 1
 cutaneous calcinosis in, 457
 diffuse, anticentromere antibodies in, 125
 interstitial lung disease in, 1254
 naifold biopsy in, 97
 naifold capillary patterns in, 458
 platelet-inhibiting drugs in, 1137
 toxic oil syndrome, eosinophilic fasciitis and, 1200
 TSK (tight skin) mouse model for, 180
 Scleroderma fibroblasts, glycosaminoglycan biosynthesis by, 1040

Sclerosis, digital, in non-insulin-dependent diabetes, 960
 Secondary hyperparathyroidism, dialysis, renal osteodystrophy and, 1086
 Septic arthritis, enterococcus in, 591
 Serine in human articular cartilage, 58
 Serine protease, proteoglycans and, in articular cartilage, 305
 Serologic markers in ankylosing spondylitis, 961
 Serotonin
 in Raynaud's phenomenon, 139
 in systemic sclerosis, 139
 Serum amyloid P, colchicine and, 349
 Sexuality in RA and ankylosing spondylitis, 217
 Shopping bag syndrome, 719
 Shoulder, renal osteodystrophy and, 1086
 Sialadenitis, focal, in Sjögren's syndrome, 147
 Sialic acid, lubrication by synovial fluid and, 552
 Sicca complex, description, 1245
 Silicone-induced disease, 1440
 Single-stranded DNA antibodies in B6-lpr/lpr and B6-+/+ mice, 545
 Sinuses, thrombosis of, in Behçet's disease, 816
 Sjögren's syndrome
 HLA-D region alloantigens in, 1245
 labial salivary gland biopsy in, 1320
 lactoferrin in, 462
 in MRL/l and MRL/n mice, 157
 T cell lymphoma and, 951
 von Willebrand factor in, 1046
 Skeletal abnormalities in Down's syndrome, 929
 Skeletal radiography, SLE and, 638
 Skin
 anticentromere antibodies and, in progressive systemic sclerosis, 125
 in avian scleroderma, 807
 fibroblasts
 CTAP-U and, 780
 intermediate filaments of in SLE, 922
 HLA-DR3 antigen in RA and, 601
 lymphocytes in, in progressive systemic sclerosis, 645
 methotrexate and, in psoriatic arthritis, 376
 in multicentric reticulohistiocytosis, 344
 platelet-inhibiting drugs in scleroderma and, 1137
 in POEMS syndrome, 1053
 rash in SLE, 132
 reticular discoloration of, in primary fibrositis, 1174
 thickening of, in PSS, 645
 in TSK mouse model of scleroderma, 180
 Small airways function in RA, 728
 in nonsmokers, 1218
 Small intestine in avian scleroderma, 807
 Smoking, small airways function and, in RA, 728
 Sodium aurothiomalate; *see also* Aurothioglucose; Gold sodium thiomalate; Gold therapy
 and HLA-Bw35 and mucocutaneous lesions in RA, 833
 Sodium dodecyl sulfate, α_2 -macroglobulin-proteinase complexes and, 897

- Sodium salicylate, GAG synthesis in canine knee cartilage and, 398
- Soft tissue
- anterior tibial, popliteal cysts and, 113
 - calcium pyrophosphate dihydrate crystal deposition and swelling of, 1428
 - of cervical spine in RA, 26
 - in early RA, 744
 - hand lesions of, 449
- Soluble natural killer cytotoxic factor in SLE, 1095
- Somatomedin, CTAP-U and, 780
- Sore throat and laryngeal involvement in RA, 873
- Speckled antinuclear antibodies, anticentromere antibodies and, 92
- Spinal cord
- computed tomography and, in RA, 26
 - knee pain in diffuse histiocytic lymphoma and, 341
- Spine
- in ankylosing spondylitis, pain in, 361
 - cervical
 - acute calcific retropharyngeal tendinitis and, 708
 - computed tomography and radiography of in RA, 26
 - in Down's syndrome, 929
 - hemodialysis and, 369
 - hyperostosis in, 564
 - ossification in, 557
 - DISH of, in ankylosing spondylitis, 570
 - fractures of, 472
 - lumbar, lesions of, hemodialysis and, 369
- Splenectomy, aspirin survival in vivo and, 422
- Splints, compliance with using, by RA patients, 1227
- Spondylarthropathy, hemodialysis and, 369
- Spontaneous autoimmune disease
- in autoimmune mice, 157
 - in MRL/l mice, 1165
- Spoon player's tibia, 357
- S-proteoglycans, CTAP-U and, 780
- SS-A/Ro antigen-antibody system, tissue substrate in, 166
- SS-B antibodies, glandular fibrosis and, in progressive systemic sclerosis-Sjögren's syndrome, 478
- Statistics, misuse of, in *Arthritis and Rheumatism*, 1018
- Sterile corneal ulceration in RA, 606
- Sternoclavicular joint in polymyalgia rheumatica, 1107
- Sternocostoclavicular hyperostosis, cervical spine in, 567
- Steroid pulse therapy, T cells and, in Still's disease, 718
- Steroids; *see* Corticosteroids
- Still's disease; *see also* Juvenile rheumatoid arthritis
- steroid pulse therapy and T cells in, 718
- Streptokinase-streptodornase, total lymphoid irradiation in RA and, 486
- Stroke, bilateral, giant cell arteritis presenting as, 819
- Structural lesions in RA, 873
- Subacute cutaneous SLE; *see also* Lupus; Systemic lupus erythematosus
- pulse methylprednisolone in, 837
- Su antigen in SLE, 1263
- Subcellular fractionation, cartilage, NTP pyrophosphohydrolase and, 193
- Subchondral erosion sites, chondroclasts and osteoclasts at, 968
- Subluxation of cervical spine in RA, 26
- Submandibular salivary gland, sialadenitis and, in Sjögren's syndrome, 161
- Sucrose, anti-F(ab')₂ antibodies in juvenile arthritis and, 330
- 6-Sulfanilamidindazole-induced arthritis in rats, 689
- Sulphydryl compounds in RA, 840
- Superoxide dismutase in RA synovial fluid, 760
- Suppressor T cells in RA with vasculitis, 752
- Symphysis pubis, renal osteodystrophy and, 1090
- Syndesmophy, in lumbar spine in DISH, 571
- Synovial biopsy
- knee, in erosive azotemic osteoarthritis, 1091
 - in POEMS syndrome, 1055
 - in polymyalgia rheumatica, 1107
 - in rheumatoid synovitis, 495
- Synovial cells
- α_2 -macroglobulin-proteinase complexes and, 897
 - canine, solubilization of ⁴⁵Ca-labeled hydroxyapatite crystals, 829
 - CTAP-U and, 780
 - hyperplasia, mitogenic effects of crystals in, 668
 - rheumatoid, chloroquine inhibition of mononuclear cell factor and, 888
- Synovial fluid
- α_2 -macroglobulin-proteinase complexes and, 897
 - basophils in, 852
 - calcium oxalate crystals in, 458
 - chemical composition of, 552
 - collagen-anticollagen immune complexes in, 1370
 - collagenase in, in RA, 897
 - CPPD crystal deposition and, 1002
 - fibroblasts in
 - ³H thymidine uptake in, 668
 - plasminogen activator, CTAP-III and, 663
 - fibronectin in, in RA and OA, 913
 - iron in, in early RA, 495
 - leukemic cells in, 1306
 - lining
 - calcium phosphate from rabbit joints and, 427
 - in polymyalgia rheumatica, 111
 - lubricating activity of, 552
 - lymphocytes in, in knee arthritis, 1157
 - lymphoid infiltrate in, in RA, 976
 - macrophages in, in early RA, 495
 - mast cells in, 841, 852
 - oxygen free radicals and hydrogen peroxide in, 760
 - in polymyalgia rheumatica, 1109
 - rheumatoid, metalloproteinases and collagenase inhibitors in, 285
 - vascularity of, 852
 - viscosity of, 552
 - wear particle-induced arthritis and, 200

- Synovial membrane lymphocytes in RA, 32
- Synovial pannus tissue, hyaline cartilage erosions and, in RA, 968
- Synovial sheath, tendon, carpal tunnel syndrome with CPPD and apatite crystals in, 1190
- Synovial villus in polymyalgia rheumatica, 1110
- Synoviocytes, interleukin-1-like factor and, 654
- Synovitis
- ESR and, in RA, 737
 - experimental, induced by α_2 -macroglobulin-proteinase complexes, 897
 - mast cells and, 841, 845, 852
 - in polymyalgia rheumatica, 1107
 - of progressive ankylosis of mice, 1411
 - rheumatoid, synovial iron in, 495
 - synovial membrane lymphocytes and, in RA, 32
- Synovium
- α_2 -macroglobulin-proteinase complexes and, 897
 - in cutaneous polyarteritis nodosa, 574
 - flexor tendon, in carpal tunnel syndrome, 1192
 - mast cells in, 841, 845, 852
 - in polymyalgia rheumatica, 1107
 - rheumatoid, cathepsin B in, 509
 - IgG synthesis in, 976
 - in wear particle-induced arthritis in rabbits, 200
- Synthetic thymic serum factor; *See* Thymuline
- System A; *see* Su antigen
- Systemic disease, distal phalangeal involvement in, 454
- Systemic lupus erythematosus; *see also* Lupus
- anticardiolipin antibody in, 1318
 - anti-DNA antibody in, 766, 1387
 - anti-F(ab')₂ antibody in, 330, 1387
 - anti-interferon activity in, 598
 - anti-T cell antibodies in, 1272
 - apheresis and, 1084
 - ARA criteria for, 530, 640
 - Bence Jones proteinuria and, 638
 - bone marrow in, 638
 - C5-derived peptides in, 631
 - C5a desarg in, 631
 - cardiolipin in, 132
 - central nervous system in, 1058
 - in children, anti-T cell antibodies in, 1272
 - clinical activity in, 132
 - coexistent rheumatic disease in, 1070
 - complement receptors in, 1321
 - complement-fixing dsDNA/anti-dsDNA immune complexes in, 320
 - cosmetic surgery and, 1
 - CRI abnormalities in, 1329
 - cutaneous lesions and neutrophil aggregating activity in, 635
 - ddDNA in, 132
 - diagnostic criteria for, 837
 - disease status in, 638
 - hepatic veno-occlusive disease in, 102
 - Systemic lupus erythematosus (*cont'd*)
 - IgA, IgG, and IgM in, 638
 - immune complexes and immune reactants in, 631
 - inferior vena cava thrombosis in, 539
 - interferon in, 597
 - intravascular leukoaggregates and endothelial injury in, 631
 - lupus band test in detection of, 382
 - monoclonal proteins in, 638
 - natural killer cells in, 1072
 - natural killer cytotoxic factor in, 1095
 - nDNA in, 132
 - neutropenia in, 631
 - neutrophils in, 631
 - pancreatitis in, 118
 - paraproteinemia in, 638
 - photosensitivity rash in, 458
 - plasmacytic dyscrasia and, 638
 - poly(dT) and poly I in, 132
 - psychosocial impact of, 13
 - renal malakoplakia in, 704
 - renal vein thrombosis in, 539
 - RNA in, 132
 - serologic reactions in, 132
 - serologic tests for, 530
 - Sjögren's syndrome in, 1245
 - skeletal radiographs and, 638
 - Su antigen in, 1263
 - subacute cutaneous, pulse methylprednisolone in, 837
 - transverse myelitis in, 1058
 - veno-occlusive disease in, anticardiolipin antibodies and, 1071
 - vimentin intermediate filaments in, 922
 - von Willebrand factor antigen levels in, 1405
- Systemic sclerosis
- hypertensive crises in, 826
 - ketanserin in Raynaud's phenomenon in, 139
 - pregnancy and, 295
 - reserpine for digital ulcers in, 1314
- T**
- T cell lymphoma in Sjögren's syndrome, 951
- T cell vasculitis in sterile corneal ulceration in RA, 612
- T cells
- anti-DNA antibody synthesis in SLE and, 766
 - autologous mixed lymphocyte response in RA and, 1234
 - in avian scleroderma, 807
 - chondrocyte proteinase release and, 79
 - collagen autoreactivity in MRL/l mice and, 313
 - cytotoxic, antibodies against, in juvenile rheumatoid arthritis, 1273
 - helper (T4), after total lymphoid irradiation in RA, 481
 - IgM synthesis, drugs and in RA, 985
 - in RA, 32
 - in skin in progressive systemic sclerosis, 645

T cells (cont'd)

- in sterile corneal ulceration in RA, 606
- steroid pulse therapy and, in Still's disease, 718
- suppressor, in RA with vasculitis, 752
- Yersinia enterocolitica* and, in Reiter's syndrome, 250
- T helper/T suppressor (T4/T8) ratio in skin in progressive systemic sclerosis, 650
- Talus, aseptic necrosis of, in pancreatitis, 1309
- Target cells, natural killer activity in SLE and, 1095
- Tear formation in autoimmune mice, Sjögren's syndrome and, 157
- Tears, artificial, in keratoconjunctivitis sicca, 459
- Telangiectasiae, digital, anticentromere antibodies and, 125
- Temporal artery, von Willebrand factor and, in giant cell arteritis, 1046
- Tendinitis
 - acute calcific of hand, confusion with periarthritis, 330
 - acute calcific retropharyngeal, neck pain and, 708
 - "shopping bag syndrome," 719
- Tendon synovial sheath, carpal tunnel syndrome with CPPD and apatite crystals in, 1190
- Testes in avian scleroderma, 807
- Tetramisole, NTP pyrophosphohydrolase in cartilage and, 186
- Thalassemia minor, arthritis in, 1076
- Thalidomide in RA, 1118
- Thiols, CTAP-U and, 780
- Thiotepa and corticosteroids in RA, 864
- Thrombocytopenia, penicillamine in RA and, 721
- Thrombophlebitis
 - in Behçet's disease, 717
 - thrombosis in SLE and, 539
- Thrombosis
 - in Behçet's disease, 816
 - in SLE, 539
- Thymectomy in myasthenia gravis, 701
- Thymidine (³HTdr), T cells, *Yersinia enterocolitica* in Reiter's syndrome and, 250
- Thymidine incorporation, total lymphoid irradiation in RA and, 486
- Thymocyte proliferation, fibroblasts and, 995
- Thymocytotoxic antibody, human natural, testing for, 599
- Thymuline in RA, 117
- Thyroid disease, autoimmune, in multicentric reticulohistiocytosis, 344
- Thyroid-stimulating hormone in adjuvant arthritis in Fisher rats, 682
- Thyroxine, antithyroid arthritis and, 227
- Tibia
 - biosynthetic activity and, in experimental OA, 388
 - pain in, and spoon playing, 357
- Tibial mass, anterior, popliteal cysts and, 113
- Tissue immune effector cells in sterile corneal ulceration in RA, 606
- Tissue substrates in SS-A/Ro antigen-antibody system, 166
- Tolmetin, time course of response in juvenile rheumatoid arthritis, 1433
- Tooth loss after total lymphoid irradiation in RA, 481
- Tophus
 - in gout, 468
 - in mitral valve, 457
- Total hip arthroplasty, work disability before and after, 410
- Total lymphoid irradiation in refractory RA, 481
- Toxic oil syndrome, scleroderma, eosinophilic fasciitis and, 1200
- Toxicity in RA
 - ant venom-treated, 277
 - gold, HLA-DR antigens and, 601, 1215
 - hydroxychloroquine, 267
 - penicillamine, 267
 - skin, HLA-DR3 and, 601
- Trabecular osteoporosis, mast cells and, 845
- Transacetylation reactions, aspirin survival in vivo and, 422
- Transcutaneous electronic nerve stimulation (TENS) in ankylosing spondylitis, 1074
- Transferrin receptors in synovial membrane lymphocytes in RA, 32
- Transverse myelitis
 - in myasthenia gravis, 701
 - in SLE, 1058
- Traumatic joint disease
 - fibronectin on articular cartilage surface and, 615
 - lubrication by synovial fluid in, 552
- Triclinic calcium pyrophosphate dihydrate (CPPD) deposition, gelatin model of, 789
- Trisomy 21, arthropathy of, 929
- Trypsin, α_2 -macroglobulin-proteinase complexes and, 897
- Trypsin-like protease, α_2 -macroglobulin in RA and, 1122
- TSK (tight skin) mouse, scleroderma model of, 180
- t-test, misuse of in articles in *Arthritis and Rheumatism*, 1018
- Tumors
 - carcinoma, primary epidermoid, 452
 - of hand
 - enchondroma, 450
 - glomus, 449
 - keratoacanthoma, 450
 - metastatic, distal phalangeal, 452

U-V

Ulcers

- digital in scleroderma
 - platelet-inhibiting drugs in, 1137
 - reserpine for, 1314
 - sterile corneal, in RA, 606
- Urate levels, hyperuricemia, RA, inflammation and, 443
- Uric acid
 - in hyperuricemia, 713
 - rheumatoid activity index and, 446
- Uric acid nephropathy, chemotherapy-induced acute, piroxicam and, 116

Urinary proteins, connective tissue activating peptide and, 780

Uronic acid
 cartilage stress and, 675
 salicylate, indomethacin, GAG synthesis and, in canine knee, 398

Valvular replacement in juvenile ankylosing spondylitis, 698

Variance as statistical tool in *Arthritis and Rheumatism*, 1018

Vascular occlusion in avian scleroderma, 807

Vascular tests of hand in scleroderma, 1137

Vasculitic skin rash in SLE, 132

Vasculitis
 autoimmunity to collagen in MRL/l mice and, 313
 cutaneous, after total lymphoid irradiation in RA, 481
 with RA, suppressor T cells in, 752
 T cells, in sterile corneal ulceration in RA, 612
 von Willebrand factor antigen levels in, 1405

Veno-occlusive disease in SLE, anticardiolipin antibodies in, 1071

Venous thrombosis in Behçet's disease, 816

Vimentin intermediate filaments in SLE, 922

Viruses
 coxsackievirus B1, Tucson strain-induced polymyositis, 433
 Epstein-Barr, RANA and, 476

Viscera, in avian scleroderma, 807

Visceral involvement and antientromere antibody in CREST syndrome, 128

Vitamin D
 in glucocorticoid-induced osteopenia, 1336
 prednisone and, in RA, 1050

Vitiligo in multicentric reticulohistiocytosis, 344

Vocal cords in RA, 873

von Willebrand factor, after glucocorticoids in giant cell arteritis, 1046

von Willebrand factor antigen in vasculitis, 1405

W-Z

Walking time in RA, 864
 after total lymphoid irradiation, 481

Water content, cartilage stress and, 675

Wegener's granulomatosis
 onset after pregnancy, 1314
 onset during pregnancy, 109

Weight loss after total lymphoid irradiation in RA, 481

White blood cells
 α_2 -macroglobulin-proteinase complexes and, 902
 essential mixed cryoglobulinemia (type II) and, 353

Work disability
 in RA, 864
 total hip arthroplasty and, 410

Wrist
 early radiography of, in RA, 744
 OA in, 1191
 renal osteodystrophy and, 1086

Xerostomia
 labial salivary gland and, in Sjögren's syndrome, 147
 after total lymphoid irradiation in RA, 481

Yersinia enterocolitica in Reiter's syndrome, T cells and, 250

Zinc in rheumatic diseases, 1073

Zonal analysis of cytoplasmic components in articular cartilage chondrocytes, 1290

1000